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Abstract 
The brain is the most lipid abundant organ in the body, with the exception of 
adipose tissue. Composed of several thousand distinct lipid species, the brain 
lipidome is unique from other organs. Brain lipids support the structural, biochemical 
and signalling functions required of the central nervous system (CNS). Strict 
maintenance of the brain lipidome is necessary for synaptic plasticity, membrane 
fluidity and signal transduction. Small perturbations in lipid composition can result 
in large phenotypic consequences, such as impaired learning, memory and cognitive 
ability. 
Neurodegenerative diseases, cognitive and behavioural disorders have been 
associated with dysregulated cerebral lipid metabolism. A growing body of evidence 
links alterations in sphingolipids, plasmalogens and numerous phospholipid classes 
with neurodegenerative disorders such as Alzheimer’s disease (AD). However, it is 
not known whether these changes are causally related with the onset and progression 
of disease, or a consequence of progressive disease pathology. Indeed, the factors 
that regulate the cerebral lipidome in physiological systems are still largely 
unknown.  
The brain is continuously exposed to plasma lipids through an extensive 
network of blood micro vessels. The brain has an obligatory requirement for selected 
plasma lipids that cannot be produced de novo. Moreover, in situ synthesis of fatty 
acids is considered to be inadequate for the brains requirements.  
Circulating lipids are found as triacylglycerols, phospholipids and cholesterol 
esters packaged within plasma lipoproteins, in addition to non-esterified fatty acids 
associated with chaperone proteins, principally albumin. The composition and 
abundance of circulating lipids are significantly influenced by dietary lipids. 
Epidemiological, clinical and animal model studies show that plasma lipids are 
associated with vascular-based neurodegenerative disorders, consistent with 
causality. Nonetheless, it is not established that changes in the brain lipidome 
precede frank evolution of neurodegenerative diseases such as AD.  
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This thesis explores the plasma-brain axis in ‘Regulation of the brain 
lipidome in health and disease’. The hypothesis is supported by an in-depth review of 
the literature presented in Chapter 1. Methodological considerations for the complex 
analytical techniques and statistical modelling are presented in Chapter 2. The main 
experimental objectives of this thesis were to investigate the plasma lipidome as a 
regulator of the cerebral lipidome, presented in Publication 1. The second primary 
objective of this thesis was to explore the potential regulatory capacity of circulating 
sphingolipids in modulating cerebral sphingolipid homeostasis, as presented in 
Publication 2. 
To explore the physiological regulatory capacity of circulating lipids on the 
cerebral lipidome, wild-type mice were subjected to a diet low in fat, or a diet 
modestly enriched in saturated fatty acids (Publication 1). Following six months on 
their respective diets, the hippocampus, cerebral cortex and plasma lipidome were 
characterised using a comprehensive lipidomics platform. Long-term consumption of 
saturated fatty acids (SFA) caused substantial alterations in the abundance of 
numerous circulating lipid classes, while the cerebral lipidome remained remarkably 
stable. An investigation of individual lipid species revealed a remodelling of acyl-
chain composition of cerebral phospholipids. Long-term consumption of the SFA 
diet was associated with a reduction in phospholipids containing highly unsaturated 
fatty acids (6 or 7 total double bonds). Concomitantly, phospholipids containing 4 or 
5 double bonds were generally increased. The hippocampus (HPF) and cerebral 
cortex (CTX) were similarly affected suggesting both regions were regulated by a 
common mechanism. The plasma lipidome was investigated as a regulator through 
multivariate-multivariable predictive models. Strong associations were observed 
between plasma lipid species containing highly unsaturated fatty acids with cerebral 
phospholipids containing similar highly unsaturated species. Similar associations 
were observed with putative arachidonic acid containing species, whereas those 
containing five double bonds showed complex associations. The overall findings 
from this study demonstrate a physiological mechanism through which circulating 
lipids regulate the cerebral lipidome. Moreover, the data indicates that long-term 
consumption of well-tolerated diets can alter the cerebral lipidome, highlighting a 
potential therapeutic pathway for some neurological disorders. 
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Elevated levels of circulating ceramides have been proposed to pathologically 
accumulate in the brain, leading to neurodegenerative disease initiation and 
progression. However, several sphingolipid metabolic pathways intersect at 
ceramides, potentially leading to accumulation. To investigate the regulation and 
interaction of circulating and cerebral ceramides, wild-type mice were randomised to 
receive dietary manipulations and sphingolipid modulating agents (Publication 2). 
Mice consuming an SFA enriched diet showed elevated levels of circulating 
ceramides and the precursor, dihydroceramides. Inhibiting sphingolipid de novo 
synthesis prevented this increase. By contrast, cerebral ceramides were unaffected by 
the SFA diet. Sphingolipid de novo synthesis inhibition reduced ceramides in the 
cerebral cortex, but not in the hippocampus. Agonism of sphingosine-1-phosphate 
receptors reduced hippocampal ceramides, but not CTX or plasma ceramides. 
Unexpectedly, negative associations were observed between HPF and plasma 
ceramides, whereas small positive correlations were observed between CTX and 
plasma. The data suggest circulating ceramides were highly regulated through de 
novo synthesis, whereas cerebral ceramide levels are tightly regulated. The principal 
findings of this study indicate that increased circulating ceramides do not lead to 
accrual of ceramides in the brain. 
The primary findings presented in Publication 1 of this thesis support the 
broad hypothesis that the plasma lipidome regulates a specific subset of lipids in the 
brain. However, the results of Publication 2 highlight a regulatory axis through 
which only specific lipid classes modulate cerebral lipid composition and 
metabolism. Taken together, the experimental data from the animal studies provide 
novel insight into regulatory mechanisms, which is informative in the context of 
neurodegenerative disease processes. The findings emphasize the importance of 
identifying plasma lipids that regulate CNS function through modulation of the 
cerebral lipidome. 
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Chapter 1 
 
1 
 
Chapter 1: Review of the Literature 
1.1 Introduction 
The brain is highly enriched in lipids, supporting structural, biochemical and 
cell signalling functions (Cermenati et al., 2015). Correct lipid composition is pivotal 
for central nervous system (CNS) homeostasis by modulating neurotransmission 
(Allen, Halverson-Tamboli, & Rasenick, 2007; Heron, Shinitzky, Hershkowitz, & 
Samuel, 1980), synaptic plasticity (Bazan, 2003a; Koudinov & Koudinova, 2001), 
ion channel activities (Chen & Gross, 1994; Tillman & Cascio, 2003), gene 
expression (de Urquiza et al., 2000) and inflammation (Farooqui, Horrocks, & 
Farooqui, 2007). A strong body of evidence from both animal and human studies 
suggest abnormal cerebral lipid metabolism is associated with neurodegenerative 
diseases (Cheng, Wang, Li, Cairns, & Han, 2013; Han, 2010), behavioural disorders 
(Muller et al., 2015; Schwarz et al., 2008) and cognitive dysfunction (Coetzee et al., 
1996). Therefore, a thorough understanding of the role of circulating lipids in 
regulating the cerebral lipidome may provide insight into therapies, biomarkers and 
diagnostic tests for said conditions.  
 
1.1.1 Lipids in the Brain 
Lipid composition of the brain is unique from other organs and biofluids. The 
brain contains numerous highly specialised cell types, with strict demands on the 
functional properties of membrane bilayers (Piomelli, Astarita, & Rapaka, 2007; 
Rohrbough & Broadie, 2005). To achieve the specialized roles, cells require a 
complex mixture of lipids in membranes. For instance, neuronal and synaptic 
junction membranes require different lipid membrane composition than 
oligodendrocytes and myelin. Myelin is a lipid-rich and multilaminar structure that 
encloses segments of axons in the brain (Figure 1), greatly enhancing propagation of 
action potentials. Constituting a large part of white matter, myelin is comprised of 
approximately 80% lipid by dry weight (O'Brien & Sampson, 1965b). Due to the 
structural role that myelin plays, the lipid composition reflects a stiffer, less fluid 
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membrane – enriched in cholesterol (COH), galactosylceramides (GalCer), sulfatides 
(SM4), plasmalogens and overall, a higher percentage of esterified saturated fatty 
acids (SFA) (Macala, Yu, & Ando, 1983; O'Brien & Sampson, 1965a). In contrast, 
neuronal and synaptic junction membranes require very high fluidity, due to lateral 
diffusion of receptors and repeated endocytotic and exocytotic events (Allen et al., 
2007; Choquet & Triller, 2003). Therefore, neuronal membranes are enriched in 
unsaturated fatty acids such as docosahexaenoic acid (DHA; 22:6n-3) (Breckenridge, 
Gombos, & Morgan, 1972; Cotman, Blank, Moehl, & Snyder, 1969). 
 
 
Figure 1. Structural and functional organisation of lipids in the brain. Top, diagram 
of neuronal cell body, axon and synapse. Left, multilaminar structure of myelin. 
Lipid membranes are highly enriched in cholesterol, glycosphingolipids and 
saturated acyl chains. Right, lipid membranes and vesicles at synapses. Lipid 
membranes are enriched with unsaturated acyl chains and exhibit a fluid behaviour. 
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A major component of brain lipids are membrane phospholipids (O'Brien & 
Sampson, 1965b). Due to their amphipathic nature, phospholipids form integral 
components of membrane bilayers. A majority of phospholipids in the brain are of 
the class glycerophospholipids, containing a glycerol backbone and up to two acyl 
chains (Figure 2). It is common for the sn-1 position to contain saturated or 
monounsaturated fatty acids, while the sn-2 position contains polyunsaturated fatty 
acids (Beermann, Mobius, Winterling, Schmitt, & Boehm, 2005). The sn-3 position 
is occupied by one of several head groups, including phosphocholine 
(phosphatidylcholine, PC), phosphorylethanolamine (phosphatidylethanolamine, 
PE), phosphoserine (phosphatidylserine, PS) and phosphoinositol 
(phosphatidylinositol, PI). Compared to peripheral tissues, a substantial proportion of 
glycerophospholipids within the brain contain an ether or vinyl-ether linkage at the 
sn-1 position (Figure 2), constituting a lipid class collectively known as 
plasmalogens. Most frequently, these ether-lipids contain a phosphocholine or 
phosphorylethanolamine headgroup. Within the brain, plasmalogens represent up to 
85% of the ethanolamine phospholipid pool in brain tissue (Han, Holtzman, & 
McKeel, 2001). 
The brain also contains a substantial quantity of sphingolipids, containing a 
sphingoid base rather than the glycerol backbone (Figure 2). The sphingoid bases 
contain a long-chain aliphatic tail, replacing the equivalent sn-1 position of 
glycerolipids. A restricted subset of fatty acids can be amide-linked to the sphingoid 
base, forming the central sphingolipid metabolite ceramides (Cer). Complex 
sphingolipids are produced through O-linking of headgroups to the 1-hydroxyl 
group, such as phosphocholine (sphingomyelin, SM) or through a glycosidic linkage 
to glucose (glucosylceramide, GluCer) or galactose (galactosylceramides, GalCer). 
Addition monosaccharides and sialic acid can be added to GluCer to produce higher-
order oligosaccharide headgroups, forming many glycosphingolipid classes referred 
to as gangliosides (Schnaar, Suzuki, & Stanley, 2009). However, over 95% of 
gangliosides in the human brain are comprised of the classes GM1, GD1a, GD1b and 
GT1b (Svennerholm & Fredman, 1980). While GalCer is a stereoisomer of GluCer, 
they are not interchangeable in the brain. Sulfatides are produced through sulfation of 
GalCer and both have been shown to be irreplaceable for myelin function (Suzuki, 
Vanier, Coetzee, & Popko, 1999).  
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Figure 2. Structure and diversity of lipid classes. Left, glycerolipids are characterized 
by presence of a glycerol backbone (red). Numerous head groups afford a multitude 
of biological roles. Right, sphingolipids are characterized by presence of a sphingoid 
backbone (red). Bottom, plasmalogens contain a vinyl ether linkage in the sn-1 
position of the glycerol backbone, while lyso-phospholipids lack an acyl chain in 
either the sn-1 or sn-2 position.  
 
The unique fatty acid composition of the brain has been known for a long 
time. The brain is enriched in specific saturated, monounsaturated and 
polyunsaturated fatty acids, while being devoid of others. Furthermore, of the fatty 
acids in the cerebral cortex, n-6 and n-3 fatty acids comprise ~8.5% and ~15%, 
respectively (Fraser, Tayler, & Love, 2010). Of these species, arachidonic acid 
(ARA; 20:4n-6) comprises approximately 60% of the n-6 fatty acids, while DHA 
comprises approximately 95 % of the n-3 fatty acids. However, humans are unable to 
de novo synthesis n-6 and n-3 fatty acids, therefore they must be consumed in the 
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diet and subsequently taken up by the brain. The structure of non-esterified fatty 
acids is illustrated in Figure 3. 
 
 
Figure 3. Structure of non-esterified fatty acids. Fatty acids can be classified into 
saturated (SFA), mono-unsaturated (MUFA) and poly-unsaturated (PUFA) fatty 
acids. Polyunsaturated fatty acids can be further separated based on the position of 
the first double bond from the methyl end (n-6 and n-3). 
 
1.2 Mechanisms of circulating lipid uptake by the brain 
The brain is the most lipid abundant organ, next to adipose tissue. Therefore, 
the uptake and synthesis of lipids in the brain is paramount to maintaining the 
structural and functional requirements of the brain. In contrast to peripheral organs, 
the brain has a vast vascular network that serves as a physical protective barrier 
between capillaries and the CNS (Ballabh, Braun, & Nedergaard, 2004). The blood-
brain barrier (BBB) is the first major obstacle for lipid uptake from the circulation 
into the brain. Endothelial cells serve as the interfacing cell, tightly apposed through 
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tight junction complexes. This tight apposition restricts paracellular transport across 
the BBB and forces substances to move transcellularly through endothelial cells 
using passive diffusion or active transport systems (Abbott, Ronnback, & Hansson, 
2006). However, the principal mechanism and rates of lipid transport across the BBB 
is still not agreed upon and highly debated. It has been suggested that circulating 
lipoproteins (Edmond, 2001; Spector, 2001), lysophospholipids (Nguyen et al., 2014) 
and non-esterified fatty acids (NEFA) (Chen et al., 2015) contribute to the pool of 
lipids available for the brain (Figure 4).  
 
1.2.1 Lipoprotein mediated uptake 
Within the aqueous environment of blood, lipids are found principally 
associated with lipoproteins, as circulating lysophospholipids and as NEFA. It has 
been suggested that lipoproteins serve as a substrate pool for cerebral lipid 
requirements but the mechanisms for this putative kinetic process is presently 
unclear. Although lipoprotein receptors are found on capillary endothelial cells of the 
brain (Martin-Nizard, Meresse, Cecchelli, Fruchart, & Delbart, 1989; Meresse, 
Delbart, Fruchart, & Cecchelli, 1989; Wyne, Pathak, Seabra, & Hobbs, 1996), few 
experimental studies suggest uptake of peripherally derived lipoproteins occurs in 
mammals (Chen, Ma, Kim, Mount, & Bazinet, 2008; Purdon, Arai, & Rapoport, 
1997; Rahman et al., 2010). When circulating lipoproteins are internalised through 
receptor mediated processes, they are often targeted for endosomal-lysosomal 
degradation (Brown & Goldstein, 1979). Edmond (2001) proposed this 
internalization and processing as an explanation for the apparent selectivity of the 
brain for specific fatty acids. However, some evidence suggests transcytosis of intact 
lipoproteins may be an alternative mechanism for lipid uptake into the brain. Indeed, 
lipoproteins have been shown to cross the BBB in drosophila (Brankatschk & Eaton, 
2010) and cell culture models are supportive of lipoprotein transcytosis (Balazs et al., 
2004; Candela et al., 2008; Goti et al., 2001). 
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Figure 4. Mechanisms of lipid uptake from plasma into the brain through the blood-
brain barrier. (1) Lipoproteins are endocytosed through interaction with lipoprotein 
receptors or non-specific pinocytotic processes. (2) Lipoprotein components are 
hydrolysed. Non-esterified fatty acids (NEFA) and lysophospholipids may diffuse into 
the brain, while cholesterol is secreted into plasma. (3) Circulating lipoproteins are 
hydrolysed by lipoprotein lipase (LPL), releasing NEFA and lysophospholipids. (4) 
NEFA may cross membrane bilayers through a passive ‘flip-flop’ mechanism or fatty 
acid transport proteins (FATP). Dissociation of NEFA from membranes is enhanced 
by fatty acid binding proteins (FABP). (5) Lysophospholipid uptake is enhanced by 
the MFSD2A transporter. 
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The Edmond model of lipoprotein uptake into cerebral endothelial cells is 
supported based on the apparent lack of evidence that circulating cholesterol enters 
the brain. When incorporated into lipoproteins, cholesterol has been shown to be 
unable to cross the blood-brain barrier (Pardridge & Mietus, 1980). A study by 
Edmond, Korsak, Morrow, Torok-Both, and Catlin (1991) fed deuterium labelled 
cholesterol to rat pups at different concentrations. The approach indicated ensures 
that labelled cholesterol is naturally incorporated into native lipoproteins and that the 
bio-distribution is physiologically relevant. The abundance of deuterium labelled 
cholesterol in peripheral tissue was increased proportionally with the concentration 
of deuterium labelled cholesterol provided in the diet. However, the concentration of 
labelled cholesterol within brain was minimal and residual amounts were suggested 
to be within cerebral capillaries rather than brain parenchyme. 
Using LDL receptor knockout mice, Chen et al. (2008) explored if LDL 
uptake is a major contributor to brain fatty acid composition. Compared to wild-type 
mice, LDLr-/- mice showed no differences in the fatty acid profile of two regions of 
the brain. Comparable results were later shown for VLDL receptor knockout mice 
(Rahman et al., 2010). These studies suggest that attenuated lipoprotein uptake via 
capillary endothelial cells does not significantly influence the brain lipidome in 
ordinary physiological conditions. An alternate interpretation is that cerebral 
capillary lipoprotein uptake does contribute to cerebral lipid homeostasis, however 
redundant pathways are capable of compensating for its absence (Figure 4).  
 
1.2.2 Non-esterified fatty acid uptake 
Several reports have suggested NEFA are readily taken up by the brain. 
Using radiolabelled fatty acids, the in vivo incorporation rate of circulating NEFA 
into the brain has been estimated. Rapoport et al. (1997) found that a rapid 
equilibrium is established between plasma fatty acid and cerebral fatty acyl-CoA 
concentrations. Following intravenous infusion of radiolabelled palmitate, the 
abundance of brain phospholipids containing radiolabelled palmitate increased with 
duration of infusion (Grange et al., 1995). The uptake is rapid, with radiolabel 
9 
 
appearing in the brain within 45 seconds. Of the radiolabelled palmitate measured in 
the brain, 80% is found esterified to phospholipids within 2 minutes (Rapoport et al., 
1997). The indicated experimental data suggests that NEFA are rapidly taken up by 
the brain and incorporated into phospholipids. However, the mechanism through 
which this occurs is presently not established. 
Two prevailing theories have evolved to explain the rapid uptake of NEFA by 
the brain: Fatty acids may passively diffuse through membranes using a ‘flip-flop’ 
mechanism (Hamilton, 2003; Higgins, 1994); or alternatively specific protein-
mediated transport mechanisms exist to facilitate fatty acid transport, such as fatty 
acid translocases and binding proteins (Glatz, Luiken, & Bonen, 2010; Schwenk, 
Holloway, Luiken, Bonen, & Glatz, 2010) (Figure 4). Indeed, several candidate fatty 
acid transporters have been identified in the brain and other organs. Most of the 
transporters identified also show long-chain-fatty-acid-CoA synthase activity and 
therefore may function in ‘metabolically trapping’ NEFA (Coe, Smith, Frohnert, 
Watkins, & Bernlohr, 1999; Falcon et al., 2010). The passive diffusion model of 
NEFA uptake from blood into the brain involve several general steps. (1) The NEFA 
enter the basolateral leaflet from blood, which may be preceded by liberation from 
albumin or lipoprotein lipase mediated hydrolysis of circulating lipoproteins (Libby 
et al., 2015). (2) Translocation from the basolateral leaflet to the apical layer. (3) 
Dissociation from the membrane to the cytosol or fatty acid binding proteins. These 
processes have been reviewed in detail, previously (Bazinet & Laye, 2014; Chen, 
Green, Orr, & Bazinet, 2008; Mitchell & Hatch, 2011; Rapoport, Chang, & Spector, 
2001; Spector, 2001). It has been speculated that transporters are required to achieve 
the rates of incorporation observed in experimental studies (Mitchell, On, Del Bigio, 
Miller, & Hatch, 2011). However, experiments using artificial membranes, which do 
not contain membrane proteins, indicate that NEFA passive diffusion through 
bilayers is not rate limiting (Kamp, Zakim, Zhang, Noy, & Hamilton, 1995). 
Furthermore, Ouellet et al. (2009) has shown that DHA and eicosapentaenoic acid 
(EPA; 20:5n3) diffusion into the brain is not saturable up to supra-physiological 
concentrations. Indeed, most studies using intravenous radiolabelled NEFA support 
the idea that the passive diffusion model of NEFA uptake is sufficient to maintain the 
brain’s lipid requirement (Chen et al., 2015).   
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1.2.3 Lyso-phospholipids 
It has been known for a long time that lyso-phosphatidylcholine (LPC) 
species in blood are taken up by brain (Thiès, Delachambre, Bentejac, Lagarde, & 
Lecerf, 1992). Further, it was suggested that DHA in the form of LPC was a 
preferential carrier of DHA for the brain (Lagarde et al., 2001). Recently, the orphan 
receptor Mfsd2a (major facilitator superfamily domain-containing protein 2A) was 
identified as a transporter for DHA in the form of LPC in the brain (Nguyen et al., 
2014) (Figure 4). Mfsd2a is found to be exclusively expressed in cerebral capillary 
endothelial cells. Furthermore, Mfsd2a knockout mice show significantly reduced 
DHA concentrations in the brain. The findings are consistent with the concept that 
Mfsd2a regulates, in part, blood-to-brain kinetics of DHA.  
 
1.2.4 Cerebral selectivity of blood-derived non-esterified fatty acids.  
The selectivity of the brain for different NEFA was proposed in the early 
1990s (Anderson, Tso, & Connor, 1994). This arose due to the apparent retention of 
a specific subset fatty acids, while other fatty acids were excluded from the brain. In 
these experiments, multiple radiolabelled fatty acids were fed through a gastric tube 
and the enrichment measured in the brain and peripheral organs (Edmond, Higa, 
Korsak, Bergner, & Lee, 1998). Peripheral organs were enriched between 4-40 % for 
the various fatty acids, while the brain showed no detectable fatty acid enrichment 
except for the essential poly-unsaturated fatty acid (PUFA) linoleic acid (LA; 
18:2n6). It was speculated that the brain contained a mechanism to selectively take 
up only essential fatty acids. Selective fatty acid transport proteins were proposed as 
the principle mechanism, however, subsequent studies provided evidence to the 
contrary (Anderson, Hohimer, & Willeke, 1993). The cerebral fatty acid composition 
appears to be principally regulated through metabolic processing (Chen et al., 2013). 
Briefly, once a fatty acid enters a cell, it can become ‘metabolically trapped’ by 
esterification to coenzyme A (CoA), through action of an acyl-CoA synthetase. The 
newly formed acyl-CoA can now be directed down several metabolic pathways: 
esterified to a vacant position of a lysophospholipid; n-acylated to sphingosine; fatty 
acid elongation and desaturation; or oxidised for energy production. 
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The brain is capable of synthesizing only a few non-essential fatty acids. 
Therefore, the primary source for many non-essential fatty acids and all essential 
fatty acids is circulating lipids. Upon entry into the brain, PUFA such as ARA and 
DHA are activated and preferentially esterified into phospholipids (Anderson & 
Connor, 1988). Whereas, non-essential fatty acids and other PUFA, such as LA, 
alpha-linolenic acid (ALA; 18:3n3) and EPA are preferentially beta-oxidised (Chen 
et al., 2013). Therefore, it is apparent that the regulation of cerebral lipids is 
controlled by a complex interplay between circulating lipids and the cerebral 
metabolic activities. 
 
1.3 Regulation of cerebral lipid composition and dietary fat 
composition 
 
1.3.1 Deficiency and supplementation of dietary n-3/n-6 fatty acids 
The brain is highly enriched in n-3 fatty acids, which are critical for cell 
structure and function. Therefore, it is not surprising that much of the literature on 
dietary modulation of cerebral lipids has focused on n-3 fatty acids. Epidemiological 
studies suggest consumption of n-3 fatty acids or foods containing them are 
associated with a lower risk of neuroinflammatory disorders such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and major depression (Messamore & 
McNamara, 2016; Wu et al., 2015; Zhang et al., 2016). However, current technology 
platforms cannot measure the dynamic changes in brain n-3 fatty acids in humans. 
Therefore, many of the assumptions regarding the role of dietary n-3 fatty acids in 
the regulation of cerebral lipids come from post-mortem studies, or relevant animal 
models. 
Studies have indicated that DHA is involved in learning and memory (Yurko-
Mauro, Alexander, & Van Elswyk, 2015), however, the cellular and molecular 
mechanisms involved are not yet understood. Some of the first described effects of 
DHA include the maintenance of membrane bilayer fluidity (Neuringer, Anderson, & 
Connor, 1988); stimulating neurogenesis and neurite outgrowth (Kawakita, 
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Hashimoto, & Shido, 2006); and promoting neuronal survival (Akbar, Calderon, 
Wen, & Kim, 2005). In addition, oxidized DHA metabolites in the brain, such as 
neuroprotectin D1, also support neuronal cell homeostasis possibly by reducing 
oxidative stress (Lukiw et al., 2005).  
Founding studies revealed cognitive and behavioural abnormalities in animals 
on n-3 fatty acid deficient diets (Carrie, Clement, de Javel, Frances, & Bourre, 
2000a; Ikemoto et al., 2001; Lim & Suzuki, 2000; Moriguchi & Salem, 2003). In 
rodent models 15 weeks of treatment on an n-3 deficient diet reduced brain DHA 
concentration by approximately 40 % (Kim, Rao, Rapoport, & Igarashi, 2011). 
Dietary deficiency of n-3 fatty acids, using an artificial rearing system from post-
natal day 2, reduces cerebral DHA as much as 60 % in rats (Lim, Hoshiba, & Salem, 
2005). Results of these studies suggest strong homeostatic adaptations in the brain 
exist to conserve DHA. To prevent loss of DHA, the rate of phospholipid 
deacylation-reacylation (membrane recycling) of DHA containing membrane 
phospholipids is reduced, while the incorporate rate of DHA from plasma is 
increased (Contreras et al., 2000). These homeostatic adaptions have been estimated 
to increase the half-life of DHA in the brain from 33 to 90 days (DeMar, Ma, Bell, & 
Rapoport, 2004a).  
To explore cerebral homeostatic mechanisms for maintaining brain DHA, 
Kim et al. (2011) fed rats graded n-3 fatty acid deficient diets. Six diets were 
prepared, ranging from 4.6 % ALA (n-3 sufficient) down to 0.2 % ALA (n-3 
deficient). Following 15 weeks of feeding, the fatty acid composition of blood, brain 
and livers of the rats were assessed. Despite a significant reduction in plasma DHA, 
the brain remained stable in lipid composition until dietary ALA was reduced to 0.8 
%. At that level of dietary intake, total plasma DHA was reduced by 54 %, while the 
brain was reduced by 11 %. This study suggests that the brain lipidome remains 
relatively stable over a wide range of dietary n-3 fatty acid availability. It is 
important to note that the n-3 deficient diets used in many animal studies may be 
physiologically extreme and may not be clinically relevant given that n-3 deficiency 
in humans is uncommon (Anderson & Connor, 1989; Bjerve, Mostad, & Thoresen, 
1987). A lack of DHA in the diet is compensated for by elongation and desaturation 
of ALA in the liver (Rapoport & Igarashi, 2009). However, this pathway is 
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considered to be inefficient in humans and it has been questioned whether it would 
be sufficient to supply the human brain. Several recent reviews have covered this in 
detail (Domenichiello, Kitson, & Bazinet, 2015).  
A frequent observation during n-3 deprivation, is the replacement of DHA by 
fatty acids that are usually uncommon in the brain (Lim et al., 2005). The n-6 fatty 
acid, docosapentaenoic acid (DPA; 22:5n-6), is produced by elongation and 
desaturation of ARA and usually found in very low concentrations in the brain. 
During n-3 fatty acid deficiency, cerebral DPA concentrations increase generally in 
proportion to the DHA reduction, notionally enabling similar amounts of total PUFA 
within the brain (Kim et al., 2011). However, the latter does not necessarily protect 
the animal from CNS deficits that may occur with n-3 deficiency (Lim et al., 2005).  
Studies of artificial membranes containing DHA or DPA indicate slight differences 
in membrane dynamics, which could influence the function of membrane proteins or 
synaptic signal transduction (Eldho, Feller, Tristram-Nagle, Polozov, & Gawrisch, 
2003). 
In studies where compensatory increases in brain DPA relative to DHA were 
indicated, the plasma concentration of DPA and DHA showed parallel changes in 
concentration. It was not known whether the increased DPA content of the brain was 
the result of increased availability due to hepatic production or the lack of 
competition of DHA. A study by Lim et al. (2005) provided artificially reared rat 
pups with an n-3 deficient diet containing preformed DPA, DHA or a mixture of the 
two. Pups receiving DHA or the DPA/DHA mixture had unchanged brain DHA 
levels, similar to dam reared pups. However, pups fed the DPA containing diet had a 
36 % loss of cerebral DHA, while DPA was 10.5-fold higher. Further studies by 
Stark, Lim, and Salem (2007) confirmed that DPA does not compete with DHA for 
incorporation into brain phospholipids. These studies confirm the requirement and 
specificity of the brain for DHA and indicate DPA only replaces DHA in the absence 
of sufficient DHA. 
The studies of dietary n-3 fatty acids and brain concentrations provide insight 
into the organ requirements of DHA, utilization of alternative fatty acids and the 
putative effectiveness of the brain to regulate DHA concentrations over a wide range 
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of blood lipid concentrations. However, the brain is composed of many different 
fatty acids, of which, ARA is significant. Deficiency of ARA is almost non-existent 
due to the high rate of consumption of the precursor fatty acid, LA. However, 
chronic deprivation of n-6 fatty acids has been explored in rats (Lin et al., 2015). 
Reducing dietary intake of LA from 28 % to 2 % reduces brain ARA concentrations 
by 15-28 %, while increasing DHA by 11-18 %. Concomitant with the decrease in 
ARA in the brain, EPA was found to be increased. Similarly, Igarashi et al. (2009) 
could not detect EPA in brain of rats receiving regular chow, but n-6 deprivation for 
15 weeks increased EPA to detectable levels. These studies highlight the complex 
metabolic processes involved in regulating cerebral n-3 and n-6 PUFA composition 
(Alashmali, Hopperton, & Bazinet, 2016). 
In the adult brain, ARA and DHA do not need to be further accumulated. 
Therefore, uptake into the brain serves the purpose of replacing fatty acids lost to 
beta-oxidation or those converted to active metabolites (Rapoport et al., 2001). 
However, numerous animal studies have reported that brain DHA levels can be 
increased by chronic consumption of DHA (Bascoul-Colombo et al., 2016; 
Labrousse et al., 2012; Skorve et al., 2015). A recent study by Bascoul-Colombo et 
al. (2016) fed mice a diet with 10-fold greater abundance of n-3 fatty acids, through 
DHA supplementation. The lipid composition of the hippocampus, cerebral cortex 
and cerebellum revealed that ARA was partially replaced by DHA in phospholipids. 
Furthermore, young and old mice fed a diet enriched in EPA and DHA for 2 months 
showed greater abundance of n-3 fatty acids in the brain (Labrousse et al., 2012). 
These studies suggest cerebral fatty acid composition may be partially malleable to 
chronic exposure to n-3 fatty acids. 
 
1.3.2 Saturated fat enriched diets 
Most studies exploring dietary regulation of the cerebral lipidome have 
focused principally on n-3 fatty acids, generally with severe dietary restriction 
models. Fewer studies have investigated the putative regulatory effects of pro-
inflammatory diets, for example diets enriched in SFA. The latter is an important 
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physiological consideration based on epidemiological studies that show an 
association between SFA intake and increased risk for neurodegenerative and indeed 
behavioural disorders (Kalmijn et al., 1997; Laitinen et al., 2006; Morris et al., 
2006). 
Saturated fat enriched diets have been associated with numerous peripheral 
organ disturbances, including insulin resistance, cardiomyopathy, non-alcoholic fatty 
liver disease and systemic inflammation (Kennedy, Martinez, Chuang, LaPoint, & 
McIntosh, 2009; Leamy, Egnatchik, & Young, 2013; Shi et al., 2006). Indeed, 
chronic consumption of high fat diets, particularly those enriched in SFA, can induce 
obesity and metabolic syndrome (Davis, Gabler, Walker-Daniels, & Spurlock, 2008; 
Rosqvist et al., 2014). The mechanism through which high fat diets induce metabolic 
disturbances is thought to include the exposure organs to excess fatty acids. 
Lipotoxicity is a term that describes the excessive lipid accumulation that occurs in 
non-adipose tissue in response to fatty acid oversupply. This ectopic lipid 
accumulation results in metabolic stress, cellular dysfunction and eventually cell 
death (Holland et al., 2011; Mayer & Belsham, 2010). Considering the widely-
accepted association between excessive lipid accumulation and cellular dysfunction, 
it appears to be a plausible mechanism that explains dietary fats and risk of 
neurodegenerative diseases. 
A substantive body of evidence suggests long-chain SFA are pro-
inflammatory and induce cellular stress in the brain (Marwarha, Claycombe, 
Schommer, Collins, & Ghribi, 2016; Milanski et al., 2009; Park et al., 2010; Takechi, 
Pallebage-Gamarallage, Lam, Giles, & Mamo, 2013b). Long term consumption of 
high fat diets has been shown to impair rats in a range of learning and memory tasks 
(Greenwood & Winocur, 1990; Winocur & Greenwood, 2005). In fact, short term 
exposure of the brain to lipids through intravenous infusion is sufficient to impair 
hippocampal energy metabolism in humans (Emmanuel et al., 2013). It is speculated 
that when the brain is exposed to high concentrations of fatty acids in the blood, 
inflammatory pathways are activated and excess fatty acids can form lipotoxic 
substrates. Saturated fatty acids, such as palmitate, are well documented to cause 
intracellular accumulation of lipids, such as long-chain acyl-CoA, Cer and 
diacylglycerols (DG) – all documented to cause insulin resistance and cellular stress 
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(Cooney, Thompson, Furler, Ye, & Kraegen, 2002; Erion & Shulman, 2010; 
Summers, 2006). Furthermore, it has been suggested that the rate of ceramide 
synthesis is primarily controlled by availability of palmitoyl-CoA, a substrate for the 
enzyme serine-palmitoyl transferase (Hanada, 2003). 
Several recent papers have explored the response of the cerebral lipidome in 
response to chronic ingestion of high fat diets. Borg, Omran, Weir, Meikle, and Watt 
(2012) fed mice a high fat diet (60 % energy from fat) for 8 weeks and measured 
lipids in the hypothalamus. Mice consuming the high fat diet showed increased 
abundance of Cer, dihydroceramides (dhCer), dihexosylceramides (DHC), DG, 
triacylglycerols (TG), alkylphosphatidylcholine (PC(O)) and bis-monoacylglycero-
phosphate (BMP). As expected, this was accompanied by activation of inflammatory 
pathways. In another study, Posey et al. (2009) showed that a high fat diet (60 % 
energy from fat) caused the accumulation of saturated long-chain acyl-CoAs in the 
hypothalamus. Both studies examined the hypothalamus, a region of the brain 
proposed to have roles in ‘fatty acid sensing’ for modulating energy intake (Pocai et 
al., 2006). The latter may predispose the region to have altered susceptibility for lipid 
accumulation (Martinez de Morentin et al., 2010).   
The hippocampal formation (HPF) is a region of the brain important for 
memory and shown to be adversely affected by high fat diets. Stranahan, Cutler, 
Button, Telljohann, and Mattson (2011) assessed the HPF lipidome in rats fed a high 
fat diet with high-fructose corn syrup in their water. After three months on the diet, 
the HPF of rats on the high fat diet has higher abundance of unesterified cholesterol, 
GalCer, Cer, SM4 and several isoforms of SM. It should be noted that only 
hippocampus tissue of animals whose serum cholesterol levels fell into the highest 
third where selected; limiting generalizability of results.  
Changes in the phospholipid fatty acyl composition has potential to highly 
influence synaptic function, independently of changes in the abundance of lipid 
classes (Spector & Yorek, 1985). Yu et al. (2010) performed a multi-generation 
feeding study with two high fat diets in mice. The cerebral fatty acid composition of 
mice fed a SFA enriched diet showed reduced PUFA and significantly greater 
abundance of SFA. Whereas the cerebral fatty acid composition of mice consuming a 
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PUFA enriched diet remained unchanged. Comparable results were demonstrated by 
Cintra et al. (2012), however mice fed the SFA enriched diet also showed greater 
abundance of MUFA in the hypothalamus. Partial substitution of dietary SFA with 
MUFA or PUFA corrected the disturbances in the cerebral lipidome, suggesting 
dietary SFA, rather than total fat load, is responsible for these observations. 
 
1.4 Involvement of circulating lipids in neurodegenerative diseases 
Early pathogenic aberrations in many neurological and neurodegenerative 
diseases show significant alterations in cerebral membrane lipids (Han, 2010; 
Schwarz et al., 2008). Earlier studies principally relied on post-mortem analysis of 
brain tissue, however more recent studies are now also describing peripheral lipid 
changes prior to onset and during progressive stages of disease (Han et al., 2011; 
Huynh, Martins, & Meikle, 2017; Mielke, Haughey, et al., 2010; Mielke et al., 2011). 
Lipidomic technologies readily enable quantitative lipidomic profiling of blood, 
however in the context of cerebral physio/pathological considerations, the relevance 
of said measures requires careful consideration of how lipids in circulation might 
regulate the brain lipidome. Potential mechanisms include via alteration of capillary 
architecture and function; a consequence of altered blood-to-brain kinetics; via 
changes in pool size; via altered cerebral metabolism of lipids; or indirectly, for 
example via changes in redox homeostasis, synthesis or response to bioactive 
proteins. 
This section provides an overview of circulating lipids that have been 
implicated as biomarkers or suggested to play an active role in some 
neurodegenerative diseases. Figure 5 illustrates associations observed between 
circulating lipids and the time course of neurodegenerative disease processes. Where 
appropriate, discussion of the evidence for these lipids as regulators of cerebral lipids 
is provided. 
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Figure 4. Associations found between circulating lipids and time course of 
neurogenerative disease processes. Circulating lipids have been found to estimate risk 
of-, stratify-, and predict phenoconversion to- Alzheimer’s disease.  
 
1.4.1 Sphingolipids 
Accumulating evidence suggests that sphingolipid metabolism is perturbed 
early in the development of many neurodegenerative diseases, including AD, PD and 
Multiple Sclerosis (Bradley-Whitman & Lovell, 2015; Farmer, Smith, Hayley, & 
Smith, 2015; Ginsberg, Rafique, Xuereb, Rapoport, & Gershfeld, 1995; Moyano et 
al., 2013). Post-mortem lipidomics analysis of AD patients brain tissue has suggested 
a range of sphingolipid abnormalities, including elevations in Cer (Cutler et al., 
2004; Han, M. Holtzman, W. McKeel, Kelley, & Morris, 2002; Katsel, Li, & 
Haroutunian, 2007); increases in sphingosine (He, Huang, Li, Gong, & Schuchman, 
2010); decreases in SM (He et al., 2010); decreased sphingosine-1-phosphate (S1P) 
(Couttas et al., 2014; He et al., 2010); and changes glycosphingolipids such as 
GalCer and SM4 (Han, M. Holtzman, et al., 2002; Wallin, Gottfries, Karlsson, & 
Svennerholm, 1989). It is well established that maintenance of sphingolipid 
metabolism is critical for neuronal function and survival (Buccoliero & Futerman, 
2003; Hirabayashi & Furuya, 2008; Mencarelli & Martinez–Martinez, 2013). 
Further, Cer have been implicated to play a key role in neurodegeneration. These 
studies highlight the importance of sphingolipid metabolism for CNS function. 
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1.4.1.1 Ceramides 
While the regulation of sphingolipids within the brain is implicated in 
progression of neurodegenerative processes, circulating sphingolipids have been 
proposed to influence the risk of developing neurodegenerative diseases (Han et al., 
2011). Several prospective studies have suggested that higher baseline levels of Cer 
are predictive of future memory impairment and increased risk of developing AD 
(Mielke et al., 2012; Mielke et al., 2016). Furthermore, increases in circulating Cer 
are associated with HPF volume loss and worsening of white matter microstructure 
(Gonzalez et al., 2016; Mielke, Haughey, et al., 2010). These studies suggest that 
circulating Cer may have a biological role in the pathogenesis of neurodegenerative 
disorders, cognitive decline and brain atrophy. 
Presently, the physiological function of circulating Cer is unclear. The 
hepatic ceramide-brain axis has been proposed to link several metabolic stresses to 
neurodegeneration (Lyn-Cook et al., 2009a). In principle, extra-cerebral sources of 
Cer, such as liver, intestine or adipose tissue can contribute to the initiation or 
pathogenesis of neurodegenerative diseases. This hypothesis suggests that circulating 
Cer can directly influence the brain, although the pathway through which circulating 
Cer pass the BBB is not known. Ceramides found in blood as a constituent of 
lipoproteins. Several lines of evidence suggest that Cer are secreted nascently with 
lipoproteins and generated in the circulation by the action of serum-
sphingomyelinases (Lightle et al., 2003; Merrill et al., 1995; Schissel et al., 1998; 
Wiesner, Leidl, Boettcher, Schmitz, & Liebisch, 2009). Both mechanisms have been 
shown to be upregulated during inflammation and insulin resistance; systemic 
pathologies that are risk factors for neurodegenerative diseases. It is not surprising 
that circulating Cer have been suggested to be a major factor for development of 
such conditions.  
The regulatory effect of circulating Cer to influence cellular Cer homeostasis 
and cell function has been investigated using several models. Boyanovsky, 
Karakashian, King, Giltiay, and Nikolova-Karakashian (2003b) was the first to show 
that Cer-enriched LDL was capable of accumulating within human microvascular 
endothelial cells, which correlated with an increased incidence of apoptosis. To 
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investigate the biological role of circulating Cer on the brain, de la Monte et al. 
(2010) delivered alternative day intraperitoneal injections of short chain Cer for two 
weeks to rat pups. This repeat dosing protocol resulted in mild diabetic symptoms, 
hyperlipidaemia, cognitive deficits and accumulation of Cer in the brain. While the 
results are striking, a limitation of the study was the use of short-chain Cer, which are 
water soluble and highly permeable of cell membranes. An investigation using more 
physiological lipid preparations was considered by Boon et al. (2013). Low-density 
lipoproteins enriched with Cer were generated and infused into mice, leading to 
development of insulin resistance and inflammation - effects causally attributed to 
increased serum Cer. The findings by Boon et al. was the first evidence indicating 
that lipoprotein-associated Cer can independently exert biological effects in vivo. 
Interestingly, the induction of insulin resistance was not accompanied by an overt 
increase in skeletal muscle Cer, however there was a trend to increased plasma 
membrane Cer. In a follow-up experiment, LDL-ceramide was shown to increase Cer 
content of cultured myocytes independently of lipoprotein uptake. This suggests that 
lipoprotein-associated Cer may exert biological effects through lipid-soluble 
exchange between lipoproteins and cellular membranes. The latter suggests 
significant sequalae for the cerebrovasculature, where sphingolipid homeostasis is 
highly indicative of protective versus dysfunctional states (Sathishkumar et al., 2005; 
Spampinato et al., 2015; Testai et al., 2014; van Doorn, Nijland, Dekker, Witte, 
Lopes-Pinheiro, et al., 2012). 
While epidemiological, cell and animal model studies support the notion that 
circulating Cer are directly involved in the initiation and progression of 
neurodegenerative diseases, few studies have explored whether endogenous 
circulating Cer can modulate cerebral Cer homeostasis per se. There have been 
several suggestions in the literature that plasma Cer are associated with cerebrospinal 
fluid Cer, although the relationship and strength have not been reported (Mielke, 
Haughey, et al., 2010; Mielke et al., 2011).  
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1.4.1.2 Glycosphingolipids 
Neurodegenerative diseases often present with substantial changes in cerebral 
glycosphingolipid concentrations. Shotgun lipidomic analysis of post-mortem 
samples of pre-clinical AD subjects brain tissue have suggested that some of the 
earliest lipid abnormalities involve glycosphingolipids (Cheng et al., 2013). 
Sulfatides, an important component of myelin, is specifically depleted at the earliest 
clinically definable stage of AD and progresses with disease severity (Couttas et al., 
2016). Interestingly, it has been found that apolipoprotein E (ApoE) plays a key role 
in SM4 transport and homeostasis (Han, Cheng, Fryer, Fagan, & Holtzman, 2003). 
Since the ApoE4 allele is a major risk factor for AD, it is thought that SM4 depletion 
may be mediated by aberrant lipoprotein kinetics within the brain (Cheng, Zhou, 
Holtzman, & Han, 2010; Han, 2007). In addition, several studies have identified 
differences in multiple gangliosides in various brain regions throughout the course of 
the disease (Chan et al., 2012a). 
While there is substantial evidence for an involvement of cerebral 
glycosphingolipid disturbances with neurodegenerative diseases, evidence for 
circulating glycosphingolipids is only beginning to be elucidated. A recent study by 
Savica et al. (2016) observed higher levels of both Cer and MHC in the plasma of 
subjects with diagnosed AD and dementia with Lewy Bodies. Similarly, Mielke et al. 
(2013) found both lipid subclasses to be elevated in the plasma of PD patients. 
Extending these observations, Chan et al. (2017) performed a comprehensive plasma 
lipidomics analysis of PD subjects compared to control subjects. Elevations in MHC 
were confirmed, however they additionally observed increases in plasma monosialo-
dihexosyl-gangliosides (GM3).   
The indicated studies highlight the evidence supporting glycosphingolipid 
dysregulation in blood as well as brain in several neurodegenerative disorders. 
However, a mechanistic link to explain concomitant changes in glycosphingolipids in 
blood and brain is missing. It is possible that changes in these complex lipids are the 
result of increased Cer levels. Alternatively, it has been suggested that in PD, 
mutations in the enzyme glucocerebrosidase result in reduced hydrolysis of GluCer 
to Cer (Sidransky et al., 2009). The incidence of glucocerobrosidase mutations is 
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estimated to be between 7 and 15 % of PD patients (Sidransky et al., 2009), 
suggesting it might not entirely account for the association of GluCer with PD risk. 
Rather, it has been suggested that GluCer is an independent risk factor for PD 
(Mielke et al., 2013). 
Currently, it is not known how circulating glycosphingolipids modulate CNS 
function. It is apparent that not all circulating glycosphingolipids have similar 
biological effects. In fact, GM1 ganglioside has been in use for treatment of many 
neurological conditions, including PD (Schneider et al., 2015; Schneider et al., 
2013). The neuroprotective effects of GM1 has been demonstrated in many animal 
experiments (Fong, Neff, & Hadjiconstantinou, 1997). In addition, GM1 
gangliosides have shown proficiency in ameliorating cerebrovascular disturbances 
(Battistin et al., 1985). Moreover, in adults it is not clear to what extent circulating 
glycosphingolipids can pass the BBB intact. Animal model studies using 
radiolabelled GM1 have shown small increases of GM1 in the brain following 
repeated dosing (Polo, Kirschner, Guidotti, & Costa, 1994). 
 
1.4.2 Plasmalogens 
The brain is highly enriched in ethanolamine plasmalogens (PE(P)), a unique 
glycerophospholipid characterised by the presence of a vinyl ether at the sn-1 
position of PE. Ethanolamine plasmalogens are a major component of myelin, 
comprising greater than 80 % of the ethanolamine phospholipid pool (Norton & 
Poduslo, 1973). The acyl composition of PE(P) differ between myelin and neuronal 
membranes, with myelin containing less unsaturated fatty acids, providing the 
compact membrane conformation required. Whereas, grey matter requires a 
membrane with higher fluidity, which is represented by the greater abundance of 
highly unsaturated fatty acids in the sn-2 position. It is expected that ethanolamine 
plasmalogens are essential for signal transduction, membrane fusion and cell-cell 
communication in the brain. 
Among the many membrane abnormalities documented in AD, plasmalogen 
deficiency is frequently indicated (Ginsberg et al., 1995; Guan et al., 1999; Han et 
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al., 2001; Igarashi et al., 2011b; Wood, Barnette, Kaye, Quinn, & Woltjer, 2015). 
Post mortem analysis of AD patients at various stages of the disease have suggested 
PE(P) deficiency occurs early in the disease (Wood et al., 2015). Han et al. (2001) 
reported that PE(P) were decreased up to 40 % in the white matter at a very early 
stage of AD and a progressive loss of grey matter plasmalogens with increasing 
disease severity. It is clear that cerebral plasmalogen deficiency is a consistent 
observation in AD subjects. 
While there has been long standing evidence of cerebral plasmalogen 
deficiency in AD, it is only recently that decreasing plasma plasmalogens are being 
reported in AD and mild cognitive impairment (MCI) subjects. Goodenowe et al. 
(2007) examined the serum concentration of PE(P) in a cohort of 324 subjects (68 
cognitive normal and 256 subjects with probably AD). Ethanolamine plasmalogens 
were decreased in the probable AD group, compared to controls and indeed, serum 
concentration was inversely correlated with AD disease severity. Linear regression 
suggested that circulating plasmalogens appear to decrease early in the initiation of 
AD. Estimates suggested reductions in plasmalogens begin to occur 7 years prior to 
the appearance of clinical symptoms. Further evidence was provided by Yamashita et 
al. (2016) who showed AD subjects had lower plasma concentrations of PE(P) 
compared to controls, particularly in PE(P) species containing DHA. Interestingly, 
Wood et al. (2016) three distinct groups could be stratified using plasma lipidomics 
in a cohort of AD and MCI patients. One of those groups was characterised by low 
plasma PE(P) levels. 
Despite the apparent relationship between cerebral and circulating 
plasmalogens, little work has been done to specifically determine what putative 
functional role peripheral plasmalogens have in AD. Fundamentally, deficiency in 
plasmalogens can occur through two pathways, decreased synthesis or increased 
degradation. Plasmalogens are produced de novo through a non-redundant 
peroxisome-dependent pathway (Meikle & Summers, 2017) and it has been 
speculated that peroxisomal function is compromised in AD (Kou et al., 2011). Some 
preliminary evidence suggests the primary cause of peripheral plasmalogen 
deficiency occurs through decreased peroxisomal production in AD patients 
(Goodenowe et al., 2007). Alternatively, increased degradation mediated by 
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oxidative stress has been suggested (Guan et al., 1999). Indeed, plasmalogens act as 
anti-oxidants in cellular membranes (Kuczynski & Reo, 2006; Stadelmann-Ingrand, 
Favreliere, Fauconneau, Mauco, & Tallineau, 2001). Membrane plasmalogens 
dramatically delay oxidative degradation of polyunsaturated fatty acid. The oxidative 
products of the vinyl ether bond in plasmalogens does not propagate the peroxidation 
reaction of unsaturated fatty acids. Therefore, plasmalogens can serve as sacrificial 
lipids in membranes to prevent excessive membrane oxidative damage. It is thus 
conceivable that oxidative stress in the brain can lead to plasmalogen deficiency. 
While it is known that the brain contains all the necessary machinery to synthesize 
plasmalogens in situ ("Biosynthesis of Plasmalogens in Brain," 2008), it is not clear 
if circulating plasmalogens and their precursors are a significant source for the brain 
(Brites, Ferreira, Ferreira da Silva, et al., 2011; Das & Hajra, 1988; Das, Holmes, 
Wilson, & Hajra, 1992). It has been suggested that correcting peripheral plasmalogen 
deficiency might be sufficient to correct a CNS deficiency i.e. restoration of CNS 
plasmalogens (Goodenowe et al., 2007). 
It is possible to augment plasmalogen levels through dietary supplementation 
of alkylglycerols. Providing this precursor avoids the requirement for de novo 
synthesis in the peroxisome. Dietary supplementation has been used in animal 
experiments as a therapeutic treatment in a number of conditions, including insulin 
resistance, inflammation, and atherosclerosis (Brites, Ferreira, da Silva, et al., 2011; 
Ifuku et al., 2012; Rasmiena et al., 2015; Zhang, Sun, Tang, Cai, & Qian, 2013). A 
recent double-blind, randomised control trial was conducted to assess whether 
supplementation with scallop-derived plasmalogens improved cognitive function in 
subjects with MCI or mild AD (Fujino et al., 2017). After 24 weeks of treatment, no 
difference in mini mental state examination-Japanese score between subjects taking 
plasmalogens versus those taking placebo was observed. Rather, subgroup analysis 
revealed mild effects only in younger female subjects with mild AD. It should be 
noted that the daily dose for this study was small, 1 mg/day. Interestingly, 
erythrocyte plasmalogens increased at only one-time point in the treatment group, 
while plasma plasmalogens tended to decrease over the course of the study.  
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1.4.3 n-3 fatty acids 
Epidemiological studies and animal experiments have provided evidence that 
higher consumption of n3-fatty acids or n-3 fatty acid containing foods decrease the 
risk of developing AD (Wu et al., 2015; Zhang et al., 2016). With some 
inconsistency in findings, post mortem brain tissue of AD patients has generally 
supported a decrease of DHA containing phospholipids within selected brain regions 
(Grimm et al., 2011; Igarashi et al., 2011a). It is often suggested that loss of cerebral 
DHA is associated with cognitive dysfunction during AD (Astarita et al., 2010). 
Further, due notionally to anti-inflammatory and anti-apoptotic effects, some suggest 
that dietary supplementation with n-3 fatty acids could replace lost brain DHA and 
promote neuronal survivability (Belkouch et al., 2016). Indeed, a large number of 
prospective clinical studies have been conducted, involving supplementation of n-3 
fatty acids in patients with MCI or AD (Freund-Levi et al., 2014; Phillips, Childs, 
Calder, & Rogers, 2015; Quinn et al., 2010). Unfortunately, clinical trials have found 
little evidence for the beneficial effects of n-3 fatty acid supplementation (Burckhardt 
et al., 2016).  
Recent evidence is suggesting that the ApoE4 allele, the major genetic risk 
factor for late-onset AD, may play a role in blood-to-brain kinetics of DHA (Vandal 
et al., 2014). It was proposed that the reduced uptake of DHA into the brain in 
individuals with the ApoE4 allele explains the lack of effect of DHA in treating AD 
(Yassine et al., 2017). However, Yassine et al. measured the regional incorporation 
rates of DHA from blood into brain using positron emission tomography, to compare 
ApoE4 carriers and non-carriers. Contrary to the expected findings, the study 
revealed that carriers of the ApoE4 allele showed a greater incorporation rate of 
DHA in grey matter. It should be noted that higher rates of DHA uptake are not 
synonymous with DHA accrual. In fact, it is believed that DHA incorporation into 
the brain is related to the turnover of DHA in the brain (Rapoport, Ramadan, & 
Basselin, 2011). It is not known whether the loss of DHA from the brain is the result 
of higher oxidative stress, beta-oxidation or conversion of DHA to active 
metabolites. Indeed, carriers of ApoE4 tend to have slightly altered whole body DHA 
homeostasis compared to non-carriers, which supports the relationship between 
ApoE4 and decreased response to DHA (Hennebelle et al., 2014). 
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1.4.4 Blood-based Lipid Biomarker Panels 
Recently, many studies have published blood-based lipid biomarker panels 
that distinguish study participants as healthy controls, MCI or AD (Fiandaca et al., 
2015; Mapstone et al., 2014; Olazaran et al., 2015; Proitsi et al., 2017; Wang et al., 
2014). Using metabolomic and lipidomic profiling of plasma/serum samples, 
predictive models can be generated to (1) provide an understanding of the biology 
underpinning a disease and (2) provide a clinically translatable model for diagnosis. 
An unfortunate side-effect of measuring large numbers of metabolites is the 
confounder of dimensionality, that is that the number of metabolites measured 
generally exceeds the number of subjects measured. Therefore, the imperative is to 
validate panels on independent cohorts. 
Beyond stratifying subjects, Mapstone et al. (2014) described a panel of 10 
plasma lipids that predicted the phenoconversion from healthy to MCI/AD within 2-3 
years. Using the prospective nature of their study, they generated a predictive model 
on a discovery cohort and validated the model of subjects enrolled at a later 
timepoints. The proposed panel was found to be over 90 % accurate, with a 
validation C statistic of 0.92 in classifying phenotypic converters. However, when 
the biomarker panel underwent independent validation by other laboratories, the 
results were unable to be replicated. Li et al. (2017) assessed the predictive panel in 
plasma samples of a prospective cohort of African Americans. While the mean 
follow-up (7.3 years) was greater than Mapstone et al., the model achieved a C 
statistic of only 0.609. In a separate validation experiment, Casanova et al. (2016) 
assessed the model in two large independent cohorts. In the Baltimore Longitudinal 
Study of Aging cohort, the panel achieved a C statistic of 0.642. Whereas, In the 
Age, Gene/Environment Susceptibility-Reykjavik cohort, the panel achieved a C 
statistic of 0.395. Furthermore, using a suite of machine learning algorithms, 
Casanova et al. were unable to create a ‘classifier’ for both cohorts.  
The panel proposed by Mapstone et al. consisted of the lipid species: PC 
36:6, PC 38:0, PC 38:6, PC 40:1, PC 40:2, PC 40:6, alkylphosphatidylcholine 
(PC(O)) 40:6, lysophosphatidylcholine (LPC) 18:2, propionyl acylcarnitine and 
C16:1-OH. It is interesting to note that (1) several of the lipids likely contain DHA, 
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which has been associated with AD previously (Lin, Chiu, Huang, & Su, 2012); and 
(2) an ether lipid is decreased in those who phenoconvert, highlighting previous 
associations between peroxisome dysfunction and AD (Goodenowe et al., 2007). 
Future research could focus on circulating lipids and their relation to brain function.  
 
1.5 Conclusion 
There is a significant body of evidence which shows that the plasma lipidome 
has regulatory effects on the abundance of specific cerebral lipid species. Associated 
changes of the brain lipidome relative to plasma abundance may reflect changes in 
kinetics across the BBB; cerebral metabolic responses and/or changes in degradation 
and efflux through cerebrospinal fluid transport. Alterations in the cerebral lipidome 
are commonly indicated in neurodegenerative disorders and increasingly implicated 
in a diagnostic or causal context. However, there remains a paucity of studies which 
have interrogated the capillary axis central to lipid kinetics. With the evolution of 
contemporary lipidomic, neuroscience, neuroimaging and psychobiology technology 
platforms significant opportunities exists to explore the interrelationship between the 
blood and brain lipidome with risk for onset and progression of neurological 
disorders.  
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Thesis hypothesis and specific objectives 
The animal model studies presented in this thesis were aimed to explore the 
associated changes in the brain lipidome relative to the plasma lipidome. A 
secondary objective was to consider whether targeted modulation of sphingolipid 
metabolism was associated with parallel modulation of peripheral and cerebral 
sphingolipids. 
 
HYPOTHESIS: The plasma lipidome has a regulatory effect of the abundance 
and composition of cerebral lipids. Long term consumption of saturated fatty 
acids is associated with aberrant sphingolipid metabolism in plasma and the 
brain. Targeted modulation of sphingolipid metabolic pathways can restore 
aberrant metabolism. 
 
The above hypothesis was investigated by the following objectives: 
 
Objective 1 
To explore the effects of long term consumption of SFA enriched diets on associated 
changes in plasma and brain lipidomes. Wild-type mice were randomised to diets 
containing differing composition of fats – a low-fat diet (4 % w/w) containing 
principally PUFA or a high-fat diet (20 % w/w) modestly enriched in SFA. After 6 
months of ad libitum consumption, the lipid composition of plasma, HPF and 
cerebral cortex (CTX) was assessed by a comprehensive lipidomics platform (HPLC-
ESI-MS/MS). Rigorous statistical analysis of lipidomes were utilised to identify 
plasma lipids that are jointly and independently associated with changes in cerebral 
lipids. 
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Objective 2 
To investigate whether targeted modulation of key lipid metabolic pathways could 
restore aberrant lipid metabolism in plasma and brain. Wild-type mice were 
randomised to dietary and pharmacological interventions targeting enzymes and 
receptors regulating sphingolipid synthesis and degradative pathways. Mice were 
assigned to one of the following treatments: chow diet, SFA enriched diet with or 
without one of the following pharmacological agents – myriocin, an inhibitor of 
sphingolipid de novo synthesis; amitriptyline, an inhibitor of acidic 
sphingomyelinase; FTY 720, a S1P receptor agonist. Alterations to sphingolipids 
were assessed in plasma, HPF and CTX using HPLC-ESI-MS/MS. Putative 
associations between circulating sphingolipids and cerebral sphingolipids were 
assessed. 
 
  
30 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
  
31 
 
Chapter 2: Methodological approaches to lipidomics 
and analysis 
2.1 Introduction 
Chapter 1 established a putative causal relationship between circulating lipids 
and regulation of the cerebral lipidome. To accomplish the objectives of this thesis, 
methods to accurately characterise changes in complex biological lipidomes must be 
utilized. Lipidomics is an emerging field involving the systematic study of lipids in 
biological systems (Bou Khalil et al., 2010; Wenk, 2005; Yang & Han, 2016). 
Cellular lipids are highly complex, with many thousands of unique lipid structures 
and abundance ranging over many orders of magnitude (Schmelzer, Fahy, 
Subramaniam, & Dennis, 2007; Shevchenko & Simons, 2010). The diverse nature of 
structure and physiochemical properties enable these compounds to fulfil many 
biological functions, including for energy storage; membrane structure or as critical 
signalling intermediates. However, this complexity poses many challenges for 
characterisation and quantitation.  
While the goal of lipidomics is the analysis of ‘whole systems’, several 
technical and practical issues constrain this approach. Recent advances in analytical 
techniques have greatly enhanced depth of coverage, however lipidomic studies are 
still restricted to analysing only a subset of known lipids. Numerous complementary 
techniques are used for investigation of cellular lipidomes, including mass 
spectrometry (MS), nuclear magnetic resonance and vibrational spectroscopy 
(Carrasco-Pancorbo, Navas-Iglesias, & Cuadros-Rodríguez, 2009; Rolim, Henrique-
Araujo, Ferraz, de Araujo Alves Dultra, & Fernandez, 2015). The development in 
electrospray ionisation (ESI) MS has accelerated lipidomics research in the past two 
decades and represents one of the most widely used technique. The versatility of 
ESI-MS systems allows development of methods to detect and quantify the large 
diversity of lipid species and classes (Blanksby & Mitchell, 2010; Wenk, 2005). 
However, highly targeted and specific approaches can preclude global analysis of 
many lipid classes. Indeed, experimental procedures are generally optimised for the 
lipid species or lipid class of interest (Merrill, Sullards, Allegood, Kelly, & Wang, 
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2005; Taguchi et al., 2005). Therefore, careful consideration of experimental 
procedures is required for characterisation of biological lipidomes. 
To address the thesis hypothesis, accurate and broad analysis of circulating 
and cerebral lipids is required. This chapter describes the methodological 
considerations for methods utilised in the proceeding chapters. Discussion of the 
main sequences in a lipidomics workflow is presented, including preparation of 
samples, accurate quantitation of lipid species and statistical modelling (Figure 6). 
 
 
Figure 6. Methodological considerations for lipidomic experiments. 
 
2.2 Sample preparation 
To obtain an accurate reflection of the biological lipidome, correct sample 
preparation is essential. Ideally, sample preparation for lipidomics simultaneously 
accomplishes several tasks: extraction and isolation of lipids; removal of 
contaminating molecules; and preparation for MS. An appropriate sample 
preparation minimizes loss of lipids, maximises ionization efficiency, is reproducible 
and ensures longevity of instrumentation. Methods must be suitable for the extraction 
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of lipids from the biological matrix and be specific for lipids of interest (Furse, 
Egmond, & Killian, 2015). 
Preparation of a biological sample for lipidomics generally involves the 
extraction and isolation of lipids. One of the most widely accepted methods of lipid 
extraction from biological specimens is the method of Folch, Lees, and Sloane 
Stanley (1957). The original method describes a two-phase liquid-liquid extraction 
process using chloroform, methanol and water. The biphasic separation forms two 
phases, a high density organic phase and an aqueous phase. High abundance proteins 
are denatured and aggregate, forming a protein ‘disk’ at the interface of the solvent 
phases. Lipids and hydrophobic metabolites are largely concentrated into the lower 
organic phase while hydrophilic metabolites partition into the upper aqueous phase. 
Isolation of the organic phase accomplishes the lipid extraction procedure. 
Modifications to Folch’s procedure have been proposed (Bligh & Dyer, 1959), 
including enhanced recovery of lipid classes by acidification (Retra et al., 2008). 
However, caution should be taken in implementing strategies to enhance recovery of 
specific lipid classes, as the recovery of other lipid classes may be compromised. 
Acidification enhances the recovery of lysophospholipids and phosphatidic acid, 
however results in hydrolysis of plasmalogens (Murphy, Stephens, Jurkowitz-
Alexander, & Horrocks, 1993; Shaikh, 1994). 
Several challenges have been associated with Folch’s procedure, including 
the reliance on halogenated solvents and partitioning of lipids to the lower organic 
phase. Chloroform has a higher density than water/methanol, is a known carcinogen 
and poses health risks for laboratory personnel (Torkelson, Oyen, & Rowe, 1976). 
Recently, several lipid extraction methods have been described which avoid the use 
of chloroform and other similar solvents. Two prominent examples include the 
method described by Matyash, Liebisch, Kurzchalia, Shevchenko, and Schwudke 
(2008) using methyl-tert-butyl ether and the method of Lofgren et al. (2012) using 1-
butanol/methanol. Both systems are based on organic solvents with low density, 
therefore causing lipids to partition to the upper phase, allowing automation with 
pipetting robots. Several comparisons of lipid extraction procedures have been 
performed (Bjerve, Daae, & Bremer, 1974; Iverson, Lang, & Cooper, 2001; Lee, 
Kind, Yoon, Fiehn, & Liu, 2014; Patterson, Ducrocq, McDougall, Garrett, & Yost, 
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2015). Several publications suggest the newer methods perform as well as that of 
Folch et al., while others suggest the newer methods perform worse in their 
effectiveness to extract lower abundant lipid classes (Alshehry et al., 2015; Reis et 
al., 2013). 
The lipid extraction procedures described above involve a phase separation 
between organic and aqueous liquids. Amphiphilic lipid classes are known to 
partition into the aqueous phase or the interface (Quarles & Folch-Pi, 1965; Schacht, 
1981; Shaikh, 1994). This results in loss of those lipid classes if only the organic 
phase is collected. Additional extractions or chromatography is required to recover 
lipids loss during biphasic extractions. To overcome loss of lipids and additional 
complexity introduced with multiple extraction procedures, single-phase extractions 
can be considered. Single-phase extraction, which does not include a phase 
separation, is generally more efficient in terms of harvesting a more comprehensive 
capture of lipids with considerable differences in polarity (Alshehry et al., 2015; Liu, 
Rochfort, & Cocks, 2016). However, this method suffers from a higher content of 
aqueous impurities. In the procedure described by Folch et al., aqueous contaminants 
are removed by mixing the sample-chloroform-methanol mixture with one quarter 
volume of water. Following the procedure of Folch et al. but omitting this step 
avoids the loss of lipids into the aqueous phase, at the expense of aqueous impurities. 
However, water contained within tissue constitutes a tertiary component of the 
extraction mixture, which will cause phase separation if not considered. It is possible 
to avoid a phase separation if the ratio of solvent mixture to water is greater than 
17:1 (Wilson et al., 2013). Therefore, a single-phase extraction yields an efficient 
procedure to extract lipids from biological specimens, if subsequent procedures are 
robust against the additional impurities. 
 
2.3 Mass spectrometry 
2.3.1 Liquid chromatography 
Two principal methods are used for analysing lipidomic samples: direct 
infusion MS, also known as shotgun lipidomics; or chromatography based 
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lipidomics, such as liquid chromatography (LC) coupled MS. Shotgun lipidomics 
consists of infusing samples directly into a mass spectrometer (Kofeler, Fauland, 
Rechberger, & Trotzmuller, 2012; Wang, Wang, Han, & Han, 2016). As all lipids 
enter the mass spectrometer simultaneously, identification of lipids relies entirely on 
discrimination by mass analysers. Given that lipids are highly complex, with many 
isobaric species and non-unique precursor/product transitions, unambiguous 
identification and quantitation of complex lipid mixtures is a challenge. Recent 
advances have aimed to overcome some of these limitations, including the 
development of intra-source separation/selective ionization (Han et al., 2006) and use 
of high resolution mass spectrometers (Ekroos, Chernushevich, Simons, & 
Shevchenko, 2002). By contrast, chromatography based systems allow complex lipid 
mixtures to be separated based on chemical or physical properties prior to entering 
the mass spectrometer. As lipid species enter the mass spectrometer at different 
times, isobaric species can be separated and retention time used as an additional 
parameter for identification (Wenk, 2005). The latter overcomes the disadvantages of 
direct infusion systems, at the expense of longer analysis time. In addition, choices in 
column chemistry and mobile phase composition allow substantial flexibility in 
system design. 
Appropriate sample preparation is required for both shotgun and 
chromatography based lipidomics. However, shotgun lipidomics has stricter 
requirements for removal of impurities (Yang & Han, 2016). Removal of salts and 
polar metabolites is critical to ensure the ionization of lipids is not suppressed (Han 
& Gross, 2005). By contrast, LC separation prior to MS is more tolerant of aqueous 
impurities. Following injection onto the column, lipids are retained, while polar 
metabolites and salts are eluted with the solvent front. These impurities can be eluted 
to waste prior to entering the mass spectrometer. Therefore, the single-phase 
extraction procedure described above is suitable for LC-MS, but not shotgun 
lipidomics. 
Liquid chromatography uses a liquid mobile phase that passes through a 
column packed with a stationary phase. Many column chemistries are available, 
exploiting different physiochemical properties. Due to the hydrophobic nature of 
lipids, the most common separation system for LC-MS based lipidomics is reverse-
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phase chromatography with a C18 column. Once injected onto the column, lipids 
adsorb to the hydrophobic stationary phase and are eluted based on the relative 
affinity with the stationary and mobile phases. Mobile phase composition can be 
formulated to achieve the required separation of lipid species (Cajka & Fiehn, 2016; 
Gao, Zhang, & Karnes, 2005; Ogiso, Suzuki, & Taguchi, 2008). The composition 
can be changed throughout the course of a run, increasing the hydrophobicity of 
mobile phase and therefore increasing the elution strength. This gradient based 
approach allows for controlled elution of lipids over a wide range of polarities. By 
contrast, greater separation of lipid species can be achieved if the mobile phase 
composition is held constant (isocratic flow) (Merlin, Gresti, Bellenger, & Narce, 
2006; Weir et al., 2013b). However, this improvement in separation is only evident 
for a narrow range of polarities and can result in long run times. Indeed, the selection 
of LC parameters, including column chemistry, mobile phase composition and run 
time, are highly dependent on goal of the experiment. Recent approaches have 
adopted multiple chromatographic runs, leveraging the advantages of both gradient 
and isocratic based approaches (Weir et al., 2013b). 
 
2.3.2 Ionization technique 
For analysis and detection by a mass spectrometer, analytes must be ionized. 
Numerous techniques exist to produce ions for mass spectrometers, however ESI is 
the most common method of coupling LC systems to mass spectrometers. By 
applying a strong electric field to a liquid passing through a capillary tube, a fine 
aerosol is produced which evaporates to produce ions (Smith, Loo, Edmonds, 
Barinaga, & Udseth, 1990). The latter technique allows the constantly flowing eluent 
of LC systems to be directly coupled to a mass spectrometer. Electrospray ionisation 
is considered a ‘soft ionisation’ technique as it results in little fragmentation of 
molecules, thus preserving information of their intact mass (Fenn, Mann, Meng, 
Wong, & Whitehouse, 1990). Ions produced by ESI are often created by addition or 
loss of hydrogen. In addition to hydrogen, adducts can form with salts or buffer 
components i.e. Na+, K+ NH4+. While large molecules can attain multiple charge 
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states, lipids tend to ionize with a single charge state. Therefore, ESI offers the 
capability to effectively ionize lipids with well characterized ionization products. 
 
2.3.3 Mass spectrometer 
Once lipids are ionized and enter a mass spectrometer, the ion signal as a 
function of m/z can be produced. Through carefully tuned electric fields, the path of 
ions can be controlled. Depending on the type of mass spectrometer, ions can be 
filtered by m/z using a quadrupole; accelerated along a flight path to measure their 
m/z; or orbited around an electrode to measure m/z ratios. These different approaches 
offer advantages and disadvantages in resolution and ion throughput (Figeys & 
Aebersold, 1997; Kofeler et al., 2012; Winger, Hofstadler, Bruce, Udseth, & Smith, 
1993).  
Quadrupole mass analysers act as mass filters by only allowing ions within a 
small m/z window to pass through (Hager & Le Blanc, 2003). By applying radio 
frequency AC voltage with a DC offset, the transmissible m/z window can be tuned 
over a wide range. To acquire a mass spectrum, the quadrupole must scan over a 
range of m/z. By contrast, time-of-flight and cyclotron based mass analysers acquire 
a mass spectrum in a single scan (Guilhaus, 1995; Michalski et al., 2011). Time-of-
flight mass analysers accelerate ions through a flight tube. Ions traverse the flight 
tube at different rates, based on mass, charge and electric field strength. Therefore, 
by measuring the arrival time of an ion at the detector, the m/z can be calculated. 
Cyclotron mass analysers capture ions in an orbit around an electrode. The 
movement of ions induces a charge which is detected and processing with a fourier 
transform to produce a mass spectrum. Consistent with the functioning of time-of-
flight and cyclotron mass analysers, mass spectrums can only be acquired on batches 
of ions. Introduction of new ions into a batch disrupts the relationship between signal 
and m/z. By contrast, quadrupole mass analysers are capable of continuously filtering 
ions. Further differences in mass analysers are found in mass resolution, with a rough 
ordering: quadrupole < time-of-flight < cyclotron. Due to the filtering action of 
quadrupoles, smaller isolation windows (higher resolution) result in decreased 
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transmission efficiency (Kofeler et al., 2012). It is possible for ion transmission to 
decrease enough to result in poor signal-to-noise ratio. Time-of-flight instruments, on 
the other hand, can have orders of magnitude better mass resolution than quadrupole 
mass analysers. However, due to the low duty cycle, time-of-flight instruments have 
considerably lower levels of sensitivity. Compared to both quadrupole and time-of-
flight mass analysers, cyclotron based mass analysers have the highest resolution. 
Interestingly, mass resolution can be increased though increasing scan time. 
However, due to the long scan times for high resolution mass spectra, these 
instruments are commonly used with direct infusion (Fhaner, Liu, Ji, Simpson, & 
Reid, 2012; Ghaste, Mistrik, & Shulaev, 2016; Kofeler et al., 2012; Schuhmann et 
al., 2012). Therefore, the higher resolution is a trade-off against prior 
chromatography separation. 
Choice of mass analyser is highly dependent on the biological question to be 
answered. For discovery based experiments, the ability to sample entire mass 
spectrums simultaneously is advantageous for identifying unknown compounds. 
Indeed, time-of-flight and cyclotron mass analysers have shown substantial use in 
this area (Dunn et al., 2013). However, quantitative measurements of known 
compounds do not require full mass spectrums to be acquired. Rather, it is desirable 
to have the properties of quadrupole mass analysers: high sensitivity, high ion 
transmission and a large, linear dynamic range. 
Mass analysers can be arranged sequentially to perform tandem mass 
spectrometry (MS/MS). The most common variant of these instruments being a triple 
quadrupole mass spectrometer. In this configuration, the first and third quadrupole 
act as mass filters, whereas the second quadrupole consists of a collision cell (Han, 
Yang, & Gross, 2012). Ions transmitted by the first quadrupole undergo collision-
induced dissociation with an inert gas, causing fragmentation of molecules. Ions 
passed through the first quadrupole are referred to as precursor ions, while ions 
passing through the third quadrupole are referred to as product ions. Fragmentation 
products can provide structural information about the precursor ions. Therefore, 
unique precursor/product transitions can be used to infer identity, or to achieve 
greater selectivity for quantitative analysis (Kitteringham, Jenkins, Lane, Elliott, & 
Park, 2009). If unique precursor/product transitions are known for lipid species, the 
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mass spectrometer can cycle through the list and thus, measure the abundance of 
these species. With a chromatography system, the transitions can be scheduled for 
the approximate retention time of the lipid, therefore reducing unnecessary scans and 
greatly improving signal-to-noise ratio. This technique has allowed the measurement 
of several hundred lipid species within a single run, provided chromatographic 
separation is adequate (Weir et al., 2013b). 
 
2.3.4 Fragmentation pattern of lipids 
To create a list of precursor/product transitions, precursor and product ion 
scans can be performed on purified samples of each lipid specie. However, this is 
impractical when the intention is to measure many lipid species. Indeed, 
experimentally derived MS/MS spectral libraries have been compiled and freely 
available for researchers (METLIN) (Kind et al., 2009; Smith et al., 2005). However, 
these databases are still far from complete. Therefore, it is common to exploit 
knowledge of the fragmentation patterns that are consistent for a specific lipid class 
(Hsu & Turk, 2009; Pulfer & Murphy, 2003). As lipids are comprised of ‘building 
blocks’, there is a substantial consistency in fragmentation pattern between lipids of 
the same lipid class (Han et al., 2012). The dominant fragmentation patterns used in 
lipidomic research involve the loss of head group. For example, a lipid specie of the 
PC class will produce a strong product ion signal at 184.1 m/z – the phosphocholine 
headgroup (Figure 7) (Hsu & Turk, 2003). Whereas a PE lipid specie will produce a 
strong product ion signal of the precursor ion minus 141 Da – the 
phosphorylethanolamine headgroup (Figure 7) (Hsu & Turk, 2008). However, not 
all lipid classes can be analysed in this manner. Sphingolipids, with the exception of 
sphingomyelin, have a tendency to produce a characteristic fragment ion of 264.2 
m/z – the long chain sphingoid base (Shaner et al., 2009a). In addition, DG and TG 
species do not show class specific fragmentation patterns, Rather, each specie must 
be characterised by the loss of an acyl chain (Hsu & Turk, 2010). That is, the 
precursor ion minus an acyl chain, or by the liberated acyl chain fragment. Negative 
ionisation mode can often be used to monitor the liberation of acyl chains as product 
ions (Figure 7). Based on these fragmentation patterns, an in-silico database with 
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MS/MS spectra has been created for over 200,000 lipid species (Kangas et al., 2012; 
Kind et al., 2013; Witting, Ruttkies, Neumann, & Schmitt-Kopplin, 2017). However, 
care should be taken to avoid indiscriminate use of such a database as instrument 
specific nuances can result in poor matches.  
 
2.3.5 Isotope distribution of lipids 
When measuring a lipid specie with a mass spectrometer, multiple m/z peaks 
can often be observed in close succession (Figure 7). These m/z peaks indicate the 
isotopic distribution of the molecule. In free-living biological systems, lipids contain 
chemical elements with isotope abundances reflecting those naturally occurring on 
earth. As most lipids are principally composed of only carbon, hydrogen, oxygen, 
phosphorus and nitrogen, it is important to account for the naturally occurring 
isotope abundance of each element. For these elements, the lightest isotopes are also 
the most abundant (Meija et al., 2016). The most abundant heavier isotope 
commonly found in lipids is carbon-13, comprising roughly 1.1 % of all carbon 
atoms. That is, for each atom of carbon, there is a 1.1 % chance it is carbon-13 rather 
than the more abundant carbon-12 (~98.9 %). Mass spectrometers are capable of 
distinguishing a lipid containing a single carbon-13 molecule from the same lipid 
without any carbon-13 atoms. While these molecules appear as separate peaks in a 
mass spectrum, the difference in biological activity is fundamentally negligible 
(Dufner & Previs, 2003). Therefore, the total abundance of a lipid specie is the sum 
of all isotope peaks (Fernandez, Des Rosiers, Previs, David, & Brunengraber, 1996).  
 
41 
 
 
Figure 7. Mass spectra of two phospholipids. PC 18:0/22:6 and PE 18:0/22:6 differ 
in mass, as illustrated in their respective isotope distributions. PC lipids show a 
characteristic 184.1 m/z ion in positive mode product ion scans, representing the 
phosphocholine head group. PE lipids show a product ion of the precursor minus 141 
m/z; the loss of phosphorylethanolamine headgroup. Negative ionisation product ion 
scans show the C18:0 and C22:6 fatty acids. 
 
As lipids contain many atoms, each with a small percentage of being a 
heavier isotope, a single lipid can be observed as having a distribution of masses. For 
larger molecules, it is possible that the most abundant m/z peak does not relate to the 
mass of the molecule made up of the most abundant isotopes of each element. This 
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occurs due to the fact that as the number of atoms increases, the probability of the 
entire molecule containing at least a one heavy isotope increases (Senko, Beu, & 
McLafferty, 1995). As most lipids are small molecules, the monoisotopic peak 
(theoretical mass without heavy isotopes) generally appears as the predominant ion. 
However, the presence of isotopic species of lipids can complicate mass 
spectrometric acquisition and analysis. Due to small differences in mass between 
lipids differing in saturation (loss or gain of 2 hydrogens; 2 Da), the isotope envelope 
of an unsaturated specie can overlap a more saturated specie (Weir et al., 2013a). 
Significant differences in lipid specie abundance can cause the isotope envelope to 
mask the existence of another lipid specie or lead to inaccurate quantitation 
(Liebisch, Lieser, Rathenberg, Drobnik, & Schmitz, 2004). It is for this reason that 
chromatographic separation of lipids differing by a single double bond is essential 
(Weir et al., 2013a). 
Code to calculate the exact mass and isotopic distribution for lipid species in 
the statistical programming language R is included in Appendix II. The probability of 
isotopic variants can be modelled by a binomial distribution (Valkenborg, Mertens, 
Lemiere, Witters, & Burzykowski, 2012). Extending this to the multinomial case 
allows determination of all possible isotope combinations (Yergey, 1983). Due to 
finite mass resolving power of mass spectrometers, isotope peaks can also be 
modelled by convolution of isotope probabilities with a Gaussian distribution of 
specified width. 
 
2.4 Quantitative lipidomics 
2.4.1 Internal standards 
Accurate quantitation in lipidomics requires a method to control for 
variability in lipid extraction, ionization efficiency and systemic drift in the mass 
spectrometer. Addition of internal standards to samples allows compensation for 
these sources of variability (Wang, Wang, & Han, 2016). However, the choice of 
internal standards is critical for accurate quantification. Ideally, internal standards 
should have similar chemical and physical properties to the lipids they are being 
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compared against, but distinguishable in mass spectra. Therefore, a stable-isotope 
labelled internal standard for each lipid specie is the optimal option for accurate 
quantitation. However, lipidomic experiments are measuring several-hundred lipid 
species per run. Therefore, it is impractical to obtain stable-isotope labelled variants 
of each lipid specie. In practice, it is common to utilise one to two internal standards 
for each lipid class. Nonetheless, stable-isotope labelled internal standards are often 
not available for every lipid class (Schmelzer et al., 2007). Therefore, non-
physiologically occurring lipid species (odd- or short-chain variants) can be used in 
their place (Lam, Tian, & Shui, 2017). 
A concern with using one/two internal standards for a lipid class, is that they 
will not accurately reflect the physiochemical properties of all the lipid species in 
that class. Indeed, acyl-chain composition can range considerably across a lipid class. 
Lipid extractions are known to vary in their specificity of lipids based on 
hydrophobicity and acyl chain composition alters the fragmentation kinetics 
(Brouwers, 2011; Reis et al., 2013; Wang, Wang, & Han, 2016). Several studies have 
attempted to characterise the extent to which these issues contribute to quantitative 
inaccuracies  (Khoury, El Banna, Tfaili, & Chaminade, 2016; Koivusalo, Haimi, 
Heikinheimo, Kostiainen, & Somerharju, 2001). Indeed, the response factor of lipids 
have been shown to differ by acyl chain composition. However, careful optimization 
of ionization and fragmentation parameters for an instrument can reduce this effect to 
a negligible amount (Kim, Wang, & Ma, 1994; Koivusalo et al., 2001; Shaner et al., 
2009b). A further concern has also been proposed for gradient based LC-MS/MS 
systems. Changes in mobile phase composition can have varying effects on 
ionization efficiency (Brouwers, 2011; Wang, Wang, & Han, 2016). If internal 
standards are eluted with a considerably different mobile phase composition than the 
analyte it is compared against, erroneous relative abundances can be obtained. An 
ideal chromatography solution achieves robust separation of lipid classes, while 
individual species of a class are eluted within a narrow window. This ensures 
analytes are eluted with a similar matrix as their internal standard. 
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2.4.2 Quality controls 
In addition to internal standards, quality controls should be in place to ensure 
systematic variation does not occur over the course of an experiment (Huynh, 
Mundra, & Meikle, 2015). To avoid systematic variation from being misrepresented 
as group differences, samples should be randomised prior to sample preparation. 
While this helps to reduce the likelihood of false positive treatment effects, it does 
not identify or control systematic sources of variation. The simplest approach to 
identifying systematic variation is to utilise quality controls – the same sample 
analysed at different points throughout an experiment. Each quality control should be 
individually processed by the same experimental procedures as each sample. This 
ensures experimental variations arising from sample preparation and mass 
spectrometric acquisition are captured. In addition to quality controls, technical 
replicates should be assessed throughout an experiment (Huynh et al., 2015). 
Technical replicates attempt to isolate variation arising from a single process. By 
repeatedly analysing a pooled lipid extract interspersed with samples, variation from 
instrumentation can be isolated. Systematic issues such as HPLC column degradation 
or progressive loss of sensitivity in the mass spectrometer are identified by assessing 
variability between technical replicate samples (Kamleh, Ebbels, Spagou, Masson, & 
Want, 2012). An increase in systematic variation contributes to non-biological 
variance and reduces power to identify important features in the resulting dataset. 
 
2.5 Challenges with lipidomics datasets 
Data processing and interpretation can represent the most challenging and 
time-consuming aspects in lipodomic experiments. Lipidomics has advanced over 
the past decade and now it is routine to measure the abundance of several hundred 
lipids within a single run. In addition, the sensitivity of mass spectrometers has 
increased, allowed the detection of lipids over many orders of magnitude. While the 
depth of coverage is appealing to biomedical scientists, statistical and bioinformatic 
strategies need to be developed to cope with the specifics of the data generated. 
Several challenges need to be addressed when dealing with lipidomic data which, 
while not exhaustive, include:  
45 
 
(1) Large ‘p’ small ‘n’. In principle, this issue occurs whenever there are more 
predictors (p) than samples (n) i.e. p > n. The ‘large p small n’ issue is one of 
the most frequently encountered problems with wide datasets. As is frequent 
in many lipidomic studies the number of predictors far exceeds the number of 
samples (p >> n). While not immediately obvious why this may be an issue to 
those unfamiliar with the methodological approach, it poses large problems 
for statistical analysis (Rubingh et al., 2006). In fact, many of the commonly 
used statistical procedures fail with large datasets generated by lipidomics 
because no unique solution exists. 
 
(2) Dimensionality. The challenge of dimensionality is related to the ‘large p 
small n’ problem, in that data with high-dimensions (many predictors and 
samples) can be computationally expensive to process. The time taken to 
process data with some algorithms can scale with the number of predictors 
squared or worse. Therefore, even with access to powerful computers, the 
processing time required can be prohibitive. Furthermore, high dimensional 
data can lead to non-convex solution spaces in many algorithms, causing 
premature stopping in local optima but not global ones (Floudas & Gounaris, 
2009). 
 
(3) Multicollinearity. Multicollinearity is a phenomenon in which predictors are 
highly correlated with each other. In linear regression models, 
multicollinearity causes β-coefficients to become unstable and small amounts 
of noise can cause large changes in coefficient estimates (Kaduk et al., 2014). 
Unfortunately, this is commonly observed in lipidomic datasets, as the large 
variety of lipid species are all products of common biosynthetic pathways and 
precursors (Wong, Chan, Kingwell, Leckie, & Meikle, 2014). Therefore, 
robust methods capable of handling multicollinearity are important for 
lipidomic data analysis (Kaduk et al., 2014). 
 
(4) Concentrations differing by orders of magnitude. Due to the sensitivity of 
mass spectrometers, the concentrations of lipids can be measured over many 
orders of magnitude. From a scientist’s point of view this is advantageous as 
lipids with a high concentration are not necessarily more or less important 
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than lipids present at low concentrations, and vice versa. Unfortunately, 
multivariate statistical techniques can overemphasize higher abundance lipids 
due to their, generally, higher variance (van den Berg, Hoefsloot, Westerhuis, 
Smilde, & van der Werf, 2006) – which leads the potential confounder of 
heteroscedasticity. 
 
(5) Heteroscedasticity. Many statistical techniques rely on the assumption of 
equal variances. Heteroscedasticity occurs when variance (or standard 
deviation) scales with the absolute value of the measurement i.e. increasing 
the abundance also increases the standard deviation. This is frequently 
observed in lipidomics datasets, particularly over the orders of magnitude 
differences in lipid concentrations measured. This can result from 
physiological biological variability or as a consequence of measuring lipids 
with a mass spectrometer – fundamentally a particle counter subject to 
poisson noise (Du et al., 2008). 
 
The above highlight several of the challenges when working with lipidomic 
datasets. While there are indeed numerous ways of overcoming these challenges, 
they often are highly constrained to the type of biological questions a researcher 
would like to ask. Furthermore, the outcome and biological interpretation can be 
impacted by decisions made during the modelling process (van den Berg et al., 
2006). 
 
2.6 Statistical procedures in lipidomics research 
2.6.1 Univariate statistical tests 
One of the most common statistical methods using in the analysis of 
lipidomics data is the comparison of means between groups/treatments. This is 
typically accomplished through consideration of one variable at a time i.e. univariate 
analysis. Most frequently, the parametric independent samples t-test is used to 
compare means, due to it’s easy of use and power (Sawilowsky, 2005). It should be 
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noted that there are several assumptions associated with this test, including the 
assumption of normally distributed data and the assumption of homogeneity of 
variances. Assumption of normality can be assessed using Shapiro-Wilk’s test, 
Kolmogorov-Smirnov’s test, Anderson-Darling’s test or many others (Anderson & 
Darling, 1954; Lilliefors, 1967; Shapiro & Wilk, 1965). In the case of non-normally 
distributed data, transformation of data can be used – however, caution should be 
used when transforming data (Giles, Albrecht, Lam, Takechi, & Mamo, 2016). 
Assumption of homogeneity of variance is commonly tested using Levene’s test or 
Browne-Forsythe test (Brown & Forsythe, 1974; Levene, 1960). Welch’s t-test is an 
alternative to the traditional t-test that does not assume equality of variances (Welch, 
1947). However, alternatives to parametric statistical tests exists and include the 
family of non-parametric tests. With less assumptions on the distribution of the data, 
non-parametric tests can show improved power with non-normally distributed data 
(Giles, Albrecht, et al., 2016). One of the most popular is the Mann-Whitney U test 
(Mann & Whitney, 1947). 
For situations where there are more than two groups that researchers wish to 
compare, the analysis of variance (ANOVA) family of statistical tests are commonly 
utilised. In one of the simplest forms, the one-way ANOVA is formulated such that 
the null hypothesis is that all groups are random samples of the same population. 
Therefore, a true alternative hypothesis is that at least one sample is sufficiently 
different. In order to investigate which group this may represent, post-hoc tests are 
conducted following a rejection of the null hypothesis in an ANOVA test. A number 
of post-hoc tests are utilised, with some correcting for multiple comparisons error 
and others not (Dunnett, 1955; Tukey, 1949). Non-parametric alternatives to the 
ANOVA exist, such as the Kruskal-Wallis one-way ANOVA (Kruskal & Wallis, 
1952). 
 
2.6.2 Multiple testing correction 
When performing many statistical tests, such as applying univariate tests to 
each lipid individually across a lipidomics dataset, the total probability of observing 
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false positives rises above the typically selected 5 % level (α = 0.05). That is, the 
expectation of observing a false positive is the number of statistical tests performed 
multiplied by 0.05. For example, in a large lipidomics datasets consisting of 300 
lipids measured across two groups, it is expected to observe statistically significant 
results (rejecting the null hypothesis) in 15 lipids which did not actually change 
(false positive). To address this issue, several approaches have been developed to 
account for multiple testing, the most common methods are family-wise error rate 
(FWER) correction and false discovery rate (FDR) correction (Krzywinski & 
Altman, 2014).  
Family-wise error rate is the probability of making a type 1 error – false 
positive. Most biological scientists are familiar with at least some of the corrective 
procedures, which include the Bonferroni procedure, Tukey’s procedure, Sidak’s 
procedure and Dunnett’s correction among others (Dunn, 1961; Dunnett, 1955; 
Tukey, 1949). These methods control the rate of false positives when conducting 
multiple hypothesis testing. However, controlling the false positive rate often comes 
at the expense of power, thereby greatly increasing the number of false negatives 
(type 2 error) (Krzywinski & Altman, 2014). In application to large datasets, the 
threshold for rejecting the null hypothesis becomes increasingly stringent. The 
simplest method, the Bonferroni correction, reduces the threshold for significance by 
dividing α by the number of tests performed (Dunn, 1961). In our hypothetical 
experiment above, the p-value threshold for significance is reduced to 0.000167 
(0.05/300). Using methods to control FWER in lipidomics datasets can be overly 
conservative and lead to very inefficient study designs. In most cases, we are willing 
to accept a certain number of false positives. This is where methods that control the 
false discover rate offer advantages. 
The false positive rate is defined as the number of positive results reported, 
that are actually false. Methods that control the false discovery rate attempt to keep 
the proportion of false positives low in comparison to the number of true positives 
(Storey, 2011). While this distinction may appear subtle, these methods have been 
shown to provide more power than FWER methods. The first FDR method described 
by Benjamini and Hochberg (1995b) has become a staple method in many fields of 
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biomedical science due to adoption of high-throughput technologies (Benjamini & 
Hochberg, 1995b).  
 
2.6.3 Regression methods 
Regression models offer the ability to use a single, or multiple, predictor 
variables to explain the variance in a dependent (outcome) variable. Interestingly, 
standard linear regression models are rarely used in lipidomic studies. This is likely 
due to the experimental designs commonly utilised. Rather, one of the most 
commonly used methods in the generation of regression models using lipidomics 
datasets is binary logistic regression (Meikle et al., 2011). Binary logistic regression 
is a statistical model where the dependent variable is categorical and can take on 
either one of two states i.e. healthy vs diseased. Lipid species are used as 
independent predictors, often alongside covariates such as age, sex, BMI etc. The 
resulting coefficients provide a measure through which the lipid species are 
associated with the outcome. In brief, logistic regression relates the log odds of the 
probability of the outcome to a linear combination of the predictor variables (Harrell, 
2015). Quite often, researchers construct many logistic regression models, where 
each lipid is considered one at a time (Meikle et al., 2011; Proitsi et al., 2015; Weir et 
al., 2013b). The repeated application of logistic regression is still susceptible to 
multiple testing error and therefore correction is required. Furthermore, due to the 
challenges outlined above, when a greater number of predictors are included than 
subjects, a solution cannot be obtained without a form of regularization applied 
(Bickel et al., 2006).  
Using lipid species as predictor variables is common. Whereas, it is rare to 
assign a lipid specie as a dependent variable (with the exception of testing for mean 
differences). Indeed, few studies have attempted to generate regression models 
explaining variation in lipidomic datasets. 
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2.6.4 Regularization methods 
When there are a larger number of predictors than observations, multi-
variable regression techniques do not work (Bickel et al., 2006). The matrix 
inversion in ordinary least squares solutions do not have a unique solution (ill-posed 
problem), therefore the algorithm fails. Regularization offers an attractive solution to 
this problem, as the addition of a regularizer term allows solutions to be attained, at 
the expense of a small amount of bias (Tibshirani, 1996). Regularization has been 
shown to reduce prediction errors, compared to unregularized models. In non-
regularized models, beta coefficients are unconstrained and can easily multiply in 
value and hence, are susceptible to very high variance. If we impose a level of 
constraint of these coefficients i.e. limiting how large they can get, we are subject to 
a level of bias however we achieve a substantially reduced variance. The result is a 
model that can have smaller prediction error than a typical ordinary least squares 
regression and higher generalizability to other datasets. 
Two regularization procedures are generally considered: least absolute 
shrinkage and selection operator (LASSO) (Tibshirani, 1996) and Tikhonov (L2) (Le 
Cessie & Van Houwelingen, 1992) regularization. It is much more common for 
LASSO to be utilised in lipidomics studies due to perceived benefits as a ‘feature 
selector’. Incorporation of LASSO causes coefficients to ‘shrink’ and forces certain 
coefficients to equal zero. This effectively removes their influence, leading to a 
sparse/simpler model. However, model coefficients can vary significantly when the 
number of observations are small and correlated features are present. If we wish to 
derive information from model coefficients, the instability of LASSO estimates is an 
undesirable feature. By contrast, L2 regularization does not perform any variable 
selection, but instead shrinks all coefficients towards zero without explicitly setting 
any to zero. This procedure allows regression to occur when the number of predictors 
exceed the number of samples and when a high degree of multicollinearity is present. 
For the purposes of predictive models, several papers suggest it outperforms LASSO 
(Steyerberg, Eijkemans, Harrell, & Habbema, 2000), but at the expense of estimating 
a large number of parameters (non-parsimonious model). Recently, a combination of 
the two paradigms was developed and called the elastic net (Zou & Hastie, 2005). 
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Lastly, an issue with regularization is the formation of the hyperparameter, 
lambda (λ). Lambda controls the amount of regularization and must be specified 
prior to analysis. Typically, this is accomplished through a cross validation 
framework which is discussed below.   
 
2.6.5 Latent Variable methods 
Multivariable linear models offer the ability to regress a continuous variable 
on a linear sum of independent variables i.e. lipid species. Regularization procedures 
allow evaluation of regression models despite multicollinearity or ill-posed models 
(p>n). Extending these models to multivariable-multivariate linear models allows the 
simultaneous evaluation of several independent variables. While this appears to 
achieve the goal of regressing whole lipidomes against each other, it comes with 
several costs. For every variable in the dependent dataset, coefficients for every 
independent variable are estimated. This leads to an exponential increase in the 
number of coefficients estimated for larger lipidomes. In fact, for lipidomes of size 
100, the number of coefficients exceed 10,000. The considerable number of 
coefficients complicates interpretation and leads to overfitting. 
One of the most commonly used multivariate procedures used in 
metabolomics and lipidomics are partial least squares (PLS) methods (Geladi & 
Kowalski, 1986; Wold, Sjöström, & Eriksson, 2001). Often referred to as a 
‘chemometric’ technique, there are several variants of PLS, including PLS-
regression, PLS-discriminant analysis (PLS-DA), orthogonal-PLS and multilevel-
PLS-DA (Checa, Bedia, & Jaumot, 2015; Gromski et al., 2015; Westerhuis, van 
Velzen, Hoefsloot, & Smilde, 2010). Partial least squares attempts to find the 
relations between two data matrices; the independent variables (X) and the dependent 
variables (Y). To achieve this, latent variables are introduced to model the 
covariance structure between the two. One of the major advantages of PLS methods 
is that it effectively handles data that is highly collinear and when there are more 
variables than samples (Chong & Jun, 2005; Gromski et al., 2015). As discussed 
earlier, lipidomics datasets often contain many highly collinear features and 
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hundreds/thousands of variables. Traditional regression techniques fail in these cases, 
unless regularization techniques are introduced.  
Construction of a PLS model involves the iterative formation of latent 
structures that capture data from many predictors in order to maximally explain 
variance in the Y matrix. As is often the case, a substantial proportion of variance 
can be explained by just a few latent components. This achieves a form of 
dimensionality reduction, not unlike principle component analysis. Using the 
constructed model, loading coefficients can be used to explore the importance of 
variables in the model (Afanador, Tran, & Buydens, 2013; Kvalheim & Karstang, 
1989). Loading and score plots are often used to investigate the relationships 
between variables and groups. Additional methods of determining variable 
importance have also been suggested, such as variable importance on projection, S-S 
plots and bootstrapped loading coefficients (Afanador et al., 2013; Mehmood, 
Liland, Snipen, & Sæbø, 2012).  
While the properties of PLS make it an attractive method for lipidomics 
analysis, there are important caveats. A PLS model can be constructed for any 
dataset, however, unlike other statistical procedures, there is no implicit measure of 
statistical significance. Indeed, it is common to see ‘goodness-of-fit’ measures (R2, 
Q2) quoted as if to describe a ‘significance’ to a model (Szymanska, Saccenti, 
Smilde, & Westerhuis, 2012). Furthermore, it is common to read ‘clear separation 
between groups’ as the only performance measure when PLS-DA is used. This is one 
of the most concerning issues with use of PLS based methods. However, this is an 
issue with how the methods are used, rather than the technique itself. Indeed, 
validation can be accomplished using double cross validation (single cross validation 
is not sufficient) and statistical significance can be formalised through permutation 
tests. Neither of these techniques are commonly used in lipidomic research, or are 
used in an insufficient context. 
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2.7 Procedures in predictive modelling 
Predictive modelling encompasses traditional statistical procedures with 
several principles that differ from explanatory modelling. A key difference is the 
models derived between these two paradigms are the predictive models are generally 
parsimonious, less optimistic and are not overfit (Shmueli, 2010). The advantage is 
that models generated may be more generalizable and applicable to datasets which 
the models were not created (Bleeker et al., 2003; Ivanescu et al., 2016).  
 
2.7.1 Cross validation 
Cross validation (CV) is often recommended as a method of assessing the 
predictive value of a statistical model. In brief, CV involves splitting a dataset into 
training and testing sets, using the training set to construct a model and assessing the 
performance on the testing set (Figure 8). In principle, CV provides an assessment of 
a model’s performance on data that it has not been trained on – that is, how well does 
the model generalize to new data (Ivanescu et al., 2016). This powerful idea is one of 
the key principles underpinning predictive modelling and highly used in the field of 
machine learning (Shmueli, 2010). 
Despite the simple idea of CV, complexity arises in alternative 
implementations of CV. The simplest approach to devising train/test splits is the 
‘leave-one-out’ CV, where a single observation is predicted from a model generated 
from all other observations. If the number of observations is n, then n models are 
created from n-1 observations and the mean performance calculated over all models. 
Generalizing this approach, the dataset can be divided into k “folds” of equal size, 
where each fold is used as the testing set once. In the simplest approach, leave-one-
out CV is k-folds CV where k=n. Simulation studies have suggested that higher 
numbers of k results in lower variance in the estimates of model performance at the 
expense of computational time (Steyerberg et al., 2001b). 
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Figure 8. Schematic of cross validation and double cross validation procedures. Top, 
cross validation involves splitting data into test and train sets. A model is constructed 
on the train dataset and performance assessed on the test dataset. An error metric can 
be recorded or a hyperparameter can be determined (not both). Bottom, double cross 
validation allows optimization of hyperparameters and unbiased performance to be 
assessed. 
 
Several measures of model performance can be assessed using CV, 
depending on the model used. In a regression context, we are principally interested in 
measuring the predictive accuracy of the model on a continuous outcome variable. 
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Therefore, mean squared error of prediction (MSEP) is a suitable performance metric 
to measure. The MSEP is the average value of the squared difference between the 
real value (test set) and the predicted value from the model. Small values of MSEP 
indicate a model with good predictive accuracy. Larger values suggest worse 
predictive accuracy and can indicate several issues, including overfitting or 
insufficient ability to capture underlying trends in the data. 
 
2.7.1.1 Hyper parameters and double cross validation 
Cross validation is not only used to measure the predictive accuracy of 
models. The CV framework also functions as a systematic way to determine the 
optimal value of hyperparameters. Hyperparameters are values that are specified for 
a statistical test, but are not specifically optimized during model creation. The classic 
example is the determination of λ in regularization procedures. In both LASSO and 
Ridge regression, the amount of regularization is continuous with λ, therefore there is 
a unique model for every value of λ. To determine the ‘optimal’ value of λ, CV is 
performed and λ tuned to provide the lowest MSEP. A similar approach can be used 
in latent variable models, such as PLS, to determine the optimal number of latent 
components. Using this approach with PLS prevents overfitting, compared with other 
ad hoc approaches. 
It should be stated that using CV for hyper-parameter optimization is not the 
same as determining predictive accuracy using CV (Ambroise & McLachlan, 2002; 
Steyerberg, Bleeker, Moll, Grobbee, & Moons, 2003a). Indeed, stating the 
“predictive accuracy” of a model which was chosen as the best among many 
alternatives is not a reflection of the model’s true predictive ability. Unfortunately, 
this distinction is not often realised (Ambroise & McLachlan, 2002). The valid 
method is to use double CV, where an internal CV is performed within each iteration 
of an external CV (Figure 8) (Steyerberg et al., 2003a). Within each internal CV, the 
optimal number of latent components is determined and the predictive ability 
assessed at the external CV stage. Unfortunately, this procedure has not been readily 
taken up and many statistical packages do not offer such solutions.  
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Code to perform double CV in the statistical programming language R has 
been included in Appendix II. 
 
2.7.2 Permutation testing 
Permutation tests consist of a formalised approach to deriving statistical tests 
when traditional tests are not available. This approach constitutes a non-parametric 
statistical test by explicitly comparing a model against an appropriately generated 
distribution of null hypothesis test statistics. Through disrupting the association 
between independent and dependent variables, the possible values of the null 
hypothesis test statistic can be determined. By approximating the null distribution of 
the test statistic, the significance of the model can be determined. As PLS methods 
do not have an inherent statistical testing procedure, we can utilize permutation 
testing to determine the significance of a model (Figure 9). 
Permutation tests are particularly relevant for PLS models. A common 
criticism of PLS-DA models is that two arbitrarily designated groups can be 
separated given a sufficient number of randomly generated variables. Indeed, larger 
numbers of random variables allows greater separation. This is often considered a 
negative trait of PLS methods. However, it shows the power of PLS models in 
finding patterns in data. To determine whether a model is obtained by chance (no 
association between X and Y matrices; null hypothesis), the true model must be able 
to perform better than data with no association between the X and Y matrices i.e. 
permuted data. This intrinsically incorporates a penalty for highly complex models 
by increasing the performance threshold when many variables are being used. 
Therefore, permutation tests for PLS models are guaranteed to have a consistent false 
positive rate, regardless of the number of variables or samples.  
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Figure 9. Construction of a permuted dataset and assessment of performance. Top, a 
permuted Y matrix is generated by randomising row order. Middle, a model is 
constructed using the original X matrix and the permuted Y matrix. Due to the 
randomised row order, any associations between X and Y matrices are due to chance. 
Bottom, the performance of the permuted models is determined across many 
permutations. The original model performance is assessed against the distribution of 
permuted model performances. 
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Two common problems are evident in the literature with the use of 
permutation tests. (1) An inappropriate null hypothesis is tested. For a permutation 
test to accurately reflect the null distribution of the test statistic, the entire statistical 
modelling procedure must be replicated, including variable selection and/or cross 
validation (Steyerberg, Bleeker, Moll, Grobbee, & Moons, 2003b; Steyerberg et al., 
2001a). Omitting these steps leads to optimistic estimates of model significance 
(Harrell, 2015). (2) A single, or too few permutations are conducted. An adequate 
number of permutations is required to approximate the null distribution of the test 
statistic. Minimum number of permutations relates to the accuracy of p-value one 
wishes to attain. However, for complex models involving variable selection or 
double CV, the computational time required to perform many permutations can be 
limiting. 
Code to perform permutation testing of PLS models in the statistical 
programming language R has been included in Appendix II. 
 
2.8 Latent variable perspective of the interaction between plasma 
and brain lipidomes  
As discussed previously, lipidomics datasets contain numerous correlated 
variables. Lipid species become correlated due to common biosynthesis pathways 
and precursors. Indeed, the correlation within lipidomes encode biological 
information. However, this correlation is often ignored. The latter is possibly due to 
difficulties in analysis and interpretation, but also due to lack of exposure of 
alternative procedures in the field of lipidomics. While traditional statistical 
procedures encourage removal of correlated features, PLS can leverage this 
covariance structure.  
To consider potential changes in the cerebral lipidome as a result of 
circulating lipids, the data analysis approach presented in this thesis has been 
designed around putative physiological mechanisms. Therefore, the relationship 
between circulating and cerebral lipids is modelled as a latent variable model 
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(Figure 10). The independent variables consist of plasma lipids and the dependent 
variables are the cerebral lipids. Connecting the two sets are several latent 
components. The latent variables model the covariance structure between the two 
variable sets. In a biological perspective, the latent variables represent the transport 
of lipids in the brain; uptake and metabolism by the BBB; remodelling of lipids 
within the brain. This unique approach implies the latent variables have biological 
meaning and the loadings attached represent the importance of a lipid to that feature. 
Indeed, the use of PLS which incorporates covariance between lipids is particularly 
appropriate for the hypothesis central to this thesis. 
 
 
Figure 10. Latent variable model of the interaction between circulating and cerebral 
lipids. Left, circulating lipids are assigned loadings to each latent variable. Middle, 
latent variables represent physiological processes involved in coupling circulating 
and cerebral lipids. Right, cerebral lipids reflect the combined effect of circulating 
lipids and the metabolic processes involved in uptake, transport and remodelling. 
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2.9 Conclusions 
There are few analytical approaches for comprehensive analysis of lipidomes. 
However, considerable methodological considerations are required given the large 
combinatory options in instrument configuration, sample preparation and approach to 
statistical analysis. Indeed, each approach offers a compromise in sensitivity, 
specificity, accuracy, number of lipids analysed and time for sample throughput. In 
these studies, in order to obtain an unbiased extraction of lipids, single phase 
chloroform:methanol (2:1 v/v) extractions were utilized. For quantitative lipidomics, 
HPLC-ESI-MS/MS using triple quadrupole mass spectrometers was chosen as the 
preferred analytical approach. These instruments provide high sensitivity and large 
dynamic ranges which are critical in measuring lipids in biological systems. 
Furthermore, high specificity of quantitation could be accomplished through 
scheduled multiple reaction monitoring of established precursor/product transitions 
and retention time. To explore associations between the plasma cerebral lipidomes, 
PLS regression models were constructed. The number of latent components were 
determined through internal CV, while predictive accuracy was determined in the 
outer CV. Formalised regression significance was computed through permutation 
tests, incorporating the double CV procedure. The well-considered and justified 
approach indicated, encompass a coordinated approach to examine the thesis 
hypothesis and achieve the thesis objectives. Methodological details are provided in 
the relevant publications presented. 
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Chapter 3: Investigation into the effects of long term 
consumption of saturated fat enriched diets on the brain 
lipidome 
The content of this chapter is covered by Publication 1: 
Giles, C., Takechi, R., Mellett, N. A., Meikle, P. J., Dhaliwal, S., & Mamo, J. C. 
(2016). The Effects of Long-Term Saturated Fat Enriched Diets on the Brain 
Lipidome. PLoS One, 11(12). doi:10.1371/journal.pone.0166964 
 
3.1 Article synopsis 
3.1.1 Background 
Epidemiological studies have suggested diets high in saturated fats are 
associated with increased risk of neurodegenerative diseases, such as Alzheimer’s 
Disease. Furthermore, dysregulation of the cerebral lipidome has been documented at 
every stage of the disease. However, it is not known whether these changes are 
causally related with the onset and progression of the disease or a consequence of the 
disease pathology. Indeed, the factors that regulate the cerebral lipidome in 
physiological systems are still largely unknown.  
As discussed in Chapter 1, the brain relies on circulating lipids for the 
formation of new lipids and replacement of lost lipids. Pathological modulation of 
the cerebral lipidome has been demonstrated in severe dietary models, yet little is 
known about changes in the plasma and cerebral lipidomes for otherwise well 
tolerated diets. Despite this mechanistic insight, no previous studies had investigated 
associations between the blood and brain lipidomes, within the same subjects.  
To investigate the ability of well tolerated diets to influence both the plasma 
and brain lipidomes and the associations between them, animal models were used. 
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3.1.2 Experimental design in brief 
Wild-type C57Bl/6J mice were randomised to receive either a standard rodent 
chow (4 % w/w fat) or a saturated fat enriched diet (20 % w/w fat). Following six 
months on their respective diets, the hippocampus, cerebral cortex and plasma were 
collected. Lipids were extracted by single-phase chloroform/methanol (2:1) 
extraction and analysed by a state of the art lipidomics platform. Separation of lipids 
was performed by reverse-phase HPLC, followed by electrospray ionisation in 
positive mode and identification with tandem mass spectrometry. The abundance of 
lipid classes and individual species were compared between mice on either diet. 
Further, multivariate predictive models were developed to find plasma lipids jointly 
and independently associated with changes in the cerebral lipidomes. 
 
3.1.3 Results in brief  
Following six months on their respective diets, mice fed the saturated fat 
enriched diet maintained similar total abundance of lipid subclasses in both regions 
of the brain, despite substantial changes in plasma lipids. Comparison of individual 
lipid species in the brain revealed changes to the acyl composition within the lipid 
subclasses PC, PE, PC(O), PC(P), PE(O), PE(P), CE, DG, PI and PS. Multivariate 
predictive models revealed strong associations between plasma lipids and both HPF 
and CTX lipids.  
 
3.1.4 Discussion and conclusion in brief 
This study explored how long-term consumption of saturated fat enriched 
diets affects the cerebral lipidome. In the hippocampus and cerebral cortex, 
substantial alterations in the acyl chain composition of numerous lipid classes was 
observed. Long term consumption of saturated fat enriched diet was associated with 
a reduction in highly unsaturated phospholipids (6 or 7 double bonds) and an 
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increase in phospholipids containing a total of 4 or 5 double bonds. It would be 
expected that this alteration results in a considerably reduced membrane fluidity, 
affecting synaptic plasticity and neural activity.  
Similar patterns of lipid change were observed in both regions of the brain, 
suggesting a common causal mechanism. It was shown that the multivariate 
predictive models, using the plasma lipidome, accounted for substantial changes in 
the brain lipidome. Collectively, these results strengthen the suggestion that plasma 
lipids are causally related to changes in the brain lipidome. This is the first time such 
an approach has been conducted, whereby in-depth lipidomics of both plasma and 
brain was collected in the same subject and associations between the two rigorously 
explored. The information gained from this study provides insight into the major 
plasma lipid species that influence cerebral lipid homeostasis. 
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Invisible Citations: 
 
den Hoedt et al. (2016) 
 
Own citations: 
(Elahy, Jackaman, et al., 2015; Elahy, Lam, et al., 2015; Giles, Albrecht, et 
al., 2016; Giles, Takechi, et al., 2016; Giles et al., 2017; Heidari Nejad et al., 2015; 
Lam et al., 2013; Lam, Takechi, Pallabage-Gamarallage, Giles, & Mamo, 2015; 
Mamo et al., 2017; Takechi, Pallebage-Gamarallage, Lam, Giles, & Mamo, 2013a; 
Takechi, Pallebage-Gamarallage, et al., 2013b; Takechi, Pallebage-Gamarallage, 
Lam, Giles, & Mamo, 2014) 
(Agrawal & Gomez-Pinilla, 2012; Alles et al., 2012; Aung et al., 2016; 
Benjamini & Hochberg, 1995a; Benoit et al., 2009; Breteler, 2000; Brites, 
Waterham, & Wanders, 2004; Carrie, Clement, de Javel, Frances, & Bourre, 2000b; 
Cheng, Chang, Wu, & Chen, 2016; Chetelat et al., 2003; Cunnane, Chouinard-
Watkins, Castellano, & Barberger-Gateau, 2013; Folch-Fortuny, Arteaga, & Ferrer, 
2015; Greenwood & Winocur, 2001; Guan, 2009; Herrero, Portero-Otin, Bellmunt, 
Pamplona, & Barja, 2001; Horrocks & Farooqui, 2004; Hsu & Kanoski, 2014; 
Kanoski & Davidson, 2011; Kramer et al., 2005; Lam et al., 2014; Le Cao, Gonzalez, 
& Dejean, 2015; Lepinay et al., 2015; Meikle et al., 2013; Moraes et al., 2009; 
Morris & Tangney, 2014; Naudi et al., 2015; Oh, Boghossian, York, & Park-York, 
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2013; Pipatpiboon, Pintana, Pratchayasakul, Chattipakorn, & Chattipakorn, 2013; 
Prospective Studies et al., 2007; Quehenberger et al., 2010; R Core Team, 2015; 
Rabiei, Bigdeli, & Rasoulian, 2013; Schaefer et al., 2006; Sparks, Kuo, Roher, 
Martin, & Lukas, 2000; Stenvinkel, Diczfalusy, Lindholm, & Heimburger, 2004; 
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3.3 Supplementary material 
 
S1 Table:  Internal standards used in tandem mass spectrometry analysis of 
lipid classes 
Lipid class or subclass 
No. of 
species 
Internal 
standard Pmola 
Dihydroceramide (dhCer) 6 dhCer 8:0 100 
Ceramide (Cer) 10 Cer 17:0 100 
Monohexocylceramide (MHC) 6 MHC 16:0 d3 50 
Dihexosylceramide (DHC) 6 DHC 16:0 d3 50 
Trihexosylceramide (THC) 6 THC 17:0 50 
GM3 ganglioside (GM3) 6 THC 17:0 50 
Sphingomyelin (SM) 21 SM 12:0 200 
Phosphatidylcholine (PC) 51 PC 13:0/13:0 100 
Alkylphosphatidylcholine (PC(O)) 19 PC 13:0/13:0 100 
Alkenylphosphatidylcholine (PC(P)) 13 PC 13:0/13:0 100 
Lysophosphatidylcholine (LPC) 22 LPC 13:0 100 
Lysoalkylphosphatidylcholine (LPC(O)) 10 LPC 13:0 100 
Phosphatidylethanolamine (PE) 20 PE 17:0/17:0 100 
Alkylphosphatidylethanolamine (PE(O)) 12 PE 17:0/17:0 100 
Alkenylphosphatidylethanolamine (PE(P)) 11 PE 17:0/17:0 100 
Lysophosphatidylethanolamine (LPE) 6 PE 14:0/0:0 100 
Phosphatidylinositol (PI) 16 PE 17:0/17:0 100 
Lysophosphatidylinositol (LPI) 4 PE 14:0/0:0 100 
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Phosphatidylserine (PS) 5 PS 17:0/17:0 100 
Phosphatidylglycerol (PG) 2 PG 17:0/17:0 100 
Cholesterol ester (CE) 25 CE 18:0 d6 1000 
Free cholesterol (COH) 1 COH d7 1000 
Diacylglycerol (DG) 26 DG 15:0/15:0 200 
Triacylglycerol (TG) 44 
TG 
17:0/17:0/17:0 100 
Bis(monoacylglycero)phosphate (BMP) 1 BMP 14:0/14:0 100 
a Amount of internal standard per sample  
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S2 Table:  Conditions for tandem mass spectrometry analysis of lipid species 
Lipid class or 
subclass Parent ion Experimentb 
Voltage settingsc 
DP EP CollE CXP 
dhCer [M+H]+ PIS, 284.3 m/z 90 30 28 10 
Cer [M+H]+ PIS, 264.3 m/z 50 10 35 12 
MHC [M+H]+ PIS, 264.3 m/z 77 10 50 12 
DHC [M+H]+ PIS, 264.3 m/z 100 10 65 12 
THC [M+H]+ PIS, 264.3 m/z 130 10 73 12 
GM3 [M+H]+ PIS, 264.3 m/z 155 10 105 16 
SM [M+H]+ PIS, 184.1 m/z 65 10 35 12 
PC [M+H]+ PIS, 184.1 m/z 100 10 45 11 
PC(O) [M+H]+ PIS, 184.1 m/z 100 10 45 11 
PC(P) [M+H]+ PIS, 184.1 m/z 100 10 45 11 
LPC [M+H]+ PIS, 184.1 m/z 90 10 38 12 
LPC(O) [M+H]+ PIS, 285.2 m/z 90 10 42 5 
PE [M+H]+ NL, 141 Da 80 10 31 7 
PE(O) [M+H]+ NL, 141 Da 80 10 31 7 
PE(P) [M+H]+ NL, 141 Da 80 10 31 7 
LPE [M+H]+ NL, 141 Da 80 10 31 7 
PI [M+NH4]
+ NL, 277 m/z 51 10 43 14 
LPI [M+NH4]
+ NL, 277 m/z 51 10 43 14 
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PS [M+H]+ NL, 185 Da 86 10 29 16 
PG [M+NH4]
+ NL, 189 Da 60 10 25 12 
CE [M+NH4]
+ PIS, 369.3 m/z 30 10 20 12 
COH [M+NH4]
+ PIS, 369.3 m/z 55 10 17 12 
DG [M+NH4]
+ NL, fatty acid 55 10 30 22 
TG [M+NH4]
+ NL, fatty acid 95 10 30 12 
BMP [M+NH4]
+ 
NL, fatty acid 
dependent 
65 10 35 5 
b PIS = precursor ion scan, NL = neutral loss scan.  
c DP = declustering potential (volts); EP = entrance potential (volts); CollE = 
collision energy (volts); CXP = collision cell exit potential (volts).  
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S3 Table. Proportion of variance explained (R2) by the first latent variable for 
the first 25 individual lipids in the hippocampus and plasma lipids. 
Hippocampus Plasma 
Lipid R2 Lipid R2 
PE 34:2 0.90 PC 39:6 0.96 
PC 36:5 0.83 LPC 22:5 0.96 
PE 40:5 0.80 LPC 20:5 0.95 
PC 34:3 0.79 CE 20:5 0.94 
PE 36:2 0.77 PC 36:5 0.94 
PC 38:6 0.76 TG 18:1/18:1/22:6 0.94 
PE 36:5 0.75 TG 16:1/18:1/18:2 0.94 
PC 38:7 0.74 PC(P) 38:6 0.93 
PI 38:6 0.74 PC 36:6 0.93 
PC 36:6 0.74 PC 38:7 0.93 
PC 40:7 0.72 TG 16:0/18:1/18:2 0.93 
DG 16:0/22:5 0.70 PC(P) 38:5 0.93 
PS 40:5 0.69 LPC 22:6 0.93 
PC 33:1 0.68 TG 16:0/18:2/18:2 0.92 
PE 34:3 0.68 PC(O) 40:7 0.92 
PE(O) 40:7 0.61 TG 18:1/18:1/18:2 0.92 
PE 40:7 0.61 PC(P) 36:5 0.91 
PC 40:6 0.60 CE 20:2 0.90 
PE 40:6 0.59 PC 38:6 0.90 
PE 38:6 0.59 PC 34:5 0.89 
PE(O) 40:6 0.58 CE 14:0 0.89 
PC 39:6 0.56 PC 37:6 0.89 
PE 36:3 0.55 TG 17:0/16:0/18:0 0.87 
PC 34:2 0.51 PE(O) 40:5 0.87 
DG 18:0/18:2 0.50 CE 17:0 0.87 
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S4 Table. Proportion of variance explained (R2) by the first latent variable for the first 
25 individual lipids in the cerebral cortex and plasma lipids. 
Cortex Plasma 
Lipid R2 Lipid R2 
PC 38:6 0.87 PC 39:6 0.96 
PE 34:2 0.85 PC 36:5 0.96 
PC 40:7 0.85 PC 38:7 0.96 
PC 38:7 0.80 CE 20:5 0.96 
PC 28:0 0.80 PC 36:6 0.96 
PE 40:7 0.79 PC 37:6 0.95 
PI 38:6 0.79 PC(P) 38:6 0.94 
PC 36:6 0.76 PC 31:0 0.94 
PE(P) 38:6 0.73 TG 16:0/18:1/18:2 0.93 
PC 40:6 0.73 PC(P) 38:5 0.93 
PC 37:6 0.72 LPC 22:6 0.93 
PS 40:5 0.71 PC(O) 40:7 0.92 
PE(P) 40:6 0.70 CE 14:0 0.92 
PC(P) 38:6 0.70 PC 38:6 0.92 
PE(O) 40:6 0.70 PC 34:5 0.92 
PE 40:6 0.69 TG 16:1/18:1/18:2 0.91 
PE 38:6 0.69 PC(P) 36:5 0.91 
PC 34:3 0.67 PI 40:6 0.91 
PC 36:5 0.65 TG 16:0/18:2/18:2 0.91 
PC(P) 34:2 0.65 TG 18:1/18:1/18:2 0.90 
PI 40:6 0.65 TG 18:1/18:1/22:6 0.90 
PC 39:6 0.64 PE(O) 40:5 0.89 
PC 39:7 0.63 LPC 20:5 0.89 
PC 34:2 0.62 LPC 22:5 0.88 
PC 35:1 0.62 TG 16:0/16:1/18:1 0.88 
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S1 Figure. Scores scatter plot for partial least squares models. 
 
Wild-type mice were fed regular chow (n=10) or a saturated fat enriched diet (n=9) 
for six months. Plasma, hippocampus and cortex lipid species were quantitated with 
LC-ESI-MS/MS. Partial least squares regression was used to identify plasma lipid 
species that account for the major sources of variation within the (A) hippocampus 
and (B) cortex. Scores scatter plot of the first latent variable for mice fed regular 
chow (squares) or a saturated fat enriched diet (triangles). The first latent variable 
score for the independent lipids (plasma) on the X-axis and the first latent variable 
score for dependent lipids (hippocampus/cortex) on the Y-axis. Scores are from the 
jack-knife resampled global model. 
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Chapter 4: Circulating ceramides and cerebral 
ceramide homeostasis 
The content of this chapter is covered by Publication 2: 
Giles, C., Takechi, R., Mellett, N. A., Meikle, P. J., Dhaliwal, S., & Mamo, J. C. 
(2017). Differential regulation of sphingolipid metabolism in plasma, 
hippocampus, and cerebral cortex of mice administered sphingolipid modulating 
agents. Journal of Neurochemistry. doi:10.1111/jnc.13964 
 
4.1 Article synopsis  
4.1.1 Background 
Aberrant sphingolipid metabolism has been implicated in the progression of 
neurodegenerative disorders. Accumulation of ceramide within the brain is suggested 
to participate in the substantial neuronal loss observed in Alzheimer’s disease. 
Within the circulation, elevated ceramides are associated with cognitive decline and 
increased risk of developing AD. Combining the two lines of evidence, it has been 
suggested that circulating ceramides may play a key role in regulating cerebral 
ceramide abundance and therefore, influence the initiation of AD. 
As ceramides are the central metabolite in the sphingolipid metabolic 
network, there are multiple pathways that regulate their abundance. Several key 
pathways have been identified that might be influential in regulating blood and brain 
ceramide concentrations. The two most well-known mechanism leading to ceramide 
accumulation are through de novo synthesis and activation of sphingomyelinases. In 
physiological systems, there is potential for trafficking of ceramides from other 
organs. A downstream metabolite of ceramides, sphingosine-1-phosphate has shown 
to protect cells from ceramide accumulation and lead to cell survival. It is now clear 
that most functions S1P are accomplished through activation of 5 extracellular facing 
receptors.  
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To consider the physiological roles of the different pathways that regulate 
ceramides, animal models were utilised. Using a suite of well-characterised 
sphingolipid modulating agents, the major pathways regulating ceramides can be 
assessed in a physiological setting.  
 
4.1.2 Experimental design in brief 
Male C57Bl/6J mice were randomised to one of five experiment groups: mice 
fed standard rodent chow; mice fed a saturated fat enriched diet (SFA); mice fed 
SFA with an inhibitor of sphingolipid de novo synthesis; mice fed SFA with an 
inhibitor of sphingomyelinase; mice fed SFA with a sphingosine-1-phosphate 
receptor agonist. Following treatment, the hippocampus, cerebral cortex and plasma 
were collected for detailed analysis of sphingolipids. The putative role of different 
sphingolipid metabolic pathways, including that of circulating ceramides, were 
assessed. 
 
4.1.3 Results in brief 
Ceramides and their precursors, dihydroceramides, were elevated in the 
plasma of mice consuming the SFA diet (~60 % increase), compared to chow fed 
mice. Inhibiting the sphingolipid de novo synthesis prevented this increase, bringing 
ceramide concentrations down to control animal levels. This decrease was 
accompanied by a substantially altered sphingolipidome, including a reduction in 
dihydroceramides, sphingomyelin and monohexosylceramides and elevation in 
dihexosylceramide and GM3 gangliosides. Inhibition of sphingomyelinase with 
amitriptyline did not affect the concentration of any sphingolipids in plasma, nor did 
the agonist of sphingosine-1-phosphate receptors. By contrast, the sphingolipids in 
the hippocampus and cerebral cortex did not change in response to the SFA diet. The 
concentration of ceramides in the cerebral cortex were reduced (~15 %) by inhibiting 
sphingolipid de novo synthesis, whereas hippocampal ceramides were reduced by 
S1P receptor agonism (~20 %). 
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Associations between circulating ceramides and cerebral associations were 
assessed individually and separated by chain length and saturation. There were 
multiple negative correlations between circulating ceramides and hippocampal 
ceramides. Whereas, several small positive correlations existed for circulating C24:1 
ceramide (a high abundance plasma isoform) and several ceramide isoforms in the 
cerebral cortex.  
 
4.1.4 Discussion and conclusion in brief 
In this study, a suite of sphingolipid modulating agents and diets were used to 
investigate the regulation and interaction of circulating and cerebral ceramides. 
Using state-of-the-art lipidomics, alterations in abundance of sphingolipids could be 
measured in plasma, hippocampus and cerebral cortex of mice fed saturated fat 
enriched diets, an inhibitor of sphingolipid de novo synthesis, inhibitor of 
sphingomyelinase or an agonist of sphingosine-1-phosphate receptors. The results 
suggest that sphingolipids in plasma are highly regulated by de novo synthesis. 
Application of de novo synthesis inhibitor reduced all simple sphingolipids, whereas 
consumption of saturated fat (containing substrates for de novo synthesis) increased 
ceramides and dihydroceramides. By contrast, sphingolipids within the brain were 
generally tightly regulated. Small decreases in ceramides were observed in the 
cerebral cortex with inhibition of de novo synthesis and in the hippocampus with S1P 
receptor agonism. 
A large body of work has implicated circulating ceramides in the 
development of cognitive decline and risk for neurodegenerative diseases. The 
hypothesis proposed is that circulating ceramides are capable of influencing 
ceramide concentration in the brain, possibly through direct deposition. However, to 
date, no studies have been conducted to explore these hypotheses, therefore this 
study was the first to explore relationships between circulating and cerebral 
sphingolipids. In contrast to expectations, there were a substantial number of 
negative correlations between circulating and hippocampal ceramides. While these 
results are not supportive of the hypothesis stated above, it does not preclude 
97 
 
circulating ceramides as influential mediators of neurodegenerative disease risk. 
Rather, the results are supportive of the notion that (1) increased circulating 
ceramides do not lead to accrual of ceramides in the brain; and (2) circulating 
ceramides are not indirect measures of cerebral ceramides. 
The information gained from this study builds on the hypotheses generated 
from cross-sectional and longitudinal studies in humans suggesting a biological 
function of circulating ceramides in neurodegenerative disease risk. Rather than 
supporting these hypotheses, the results highlight a gap in our understanding of how 
these lipids influence the brain. Future research should endeavour to delineate the 
mechanisms through which this risk is pronounced, possibly with a focus on the 
BBB which has shown vulnerability for ceramide accrual. 
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Chapter 5: General discussion, limitations and future 
directions 
The final chapter of this thesis includes a general discussion to deliberate the 
major results reported in the animal model studies presented in Chapters 3 and 4. 
This chapter discusses potential mechanisms and significance of the findings in how 
circulating lipids have a homeostatic role in cerebral lipid metabolism. In addition, 
the limitations relevant to each of the studies presented as part of this thesis are 
addressed, followed by the consideration of potential future study directions. 
 
5.1 General Discussion 
The fundamental findings of Chapter 3 support the broad thesis hypothesis 
that the plasma lipidome have regulatory effects on the abundance of specific 
cerebral lipid species. Comprehensive lipidomics enabled the characterisation of 
associated changes in the cerebral lipidome relative to the plasma lipidome. The key 
results demonstrate a highly-regulated axis through which plasma lipids modulate a 
subset of cerebral lipids. For the first time, the plasma lipids that are jointly and 
independently responsible for this regulation capacity have been identified. The 
subset of cerebral lipids modulated are critical for many of the cellular functions of 
neurons and synaptic plasticity (Bazan, 2003b; Bazinet & Laye, 2014). Indeed, 
cerebral lipid homeostasis is associated with cognitive function and synaptic 
plasticity (Alashmali et al., 2016; Bazinet & Laye, 2014; Lim et al., 2005). 
Epidemiological studies have found associations between plasma lipids and cognitive 
and behavioural disorders as well as neurodegenerative disease risk (Huynh et al., 
2017; Zhang et al., 2016). The results from this study provide a framework for 
interpreting said studies, by highlighting the interrelationships between blood and 
brain lipidomes. 
The work presented in Chapter 4 investigated the regulatory effects of 
circulating sphingolipids in influencing cerebral sphingolipid homeostasis. 
Epidemiological, cellular and animal model studies suggested circulating 
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sphingolipids are involved in the initiation and progression of many neurological 
disorders (Mielke, Haughey, et al., 2010; Mielke et al., 2016). Using an animal 
model of perturbed peripheral sphingolipid metabolism in combination with 
sphingolipid modulating agents, we observed numerous inverse associations between 
circulating and HPF Cer. By contrast, a few positive associations were identified 
between circulating and CTX Cer. The results of this study highlight a gap in our 
understanding of how circulating sphingolipids are associated with brain lipid 
metabolic processes.  
 
5.1.1 Uptake of circulating lipids by the brain 
The brain is highly enriched in lipids, supporting structural, biochemical and 
cell signalling functions. Critical maintenance of cerebral lipid composition is pivotal 
for central nervous system function. It has been known for a long time that in situ 
synthesis of fatty acids is inadequate for the brain, therefore the transport, 
metabolism and uptake of fatty acids into the brain has been studied for more than a 
century (Chen et al., 2015; Grey, 1913; Rapoport, 2001). While much progress has 
been made, many fundamental questions are still unresolved.  
The first major obstacle for lipid uptake by the brain is the BBB, a highly 
active interface between blood and the brain. The restrictive nature of the BBB 
allows a level of control over transport of metabolites. The mechanisms by which 
lipids are taken up by the brain are slowly being elucidated, however there is 
considerable debate. Three major routes of uptake have been suggested to occur in 
the brain: lipoprotein mediated uptake, receptor mediated uptake of lyso-
phospholipids and uptake of non-esterified fatty acids. Most studies have attempted 
to quantify the rates of uptake through these alternative pathways using radiolabelled 
lipids (DeGeorge, Noronha, Bell, Robinson, & Rapoport, 1989; DeMar, Ma, Bell, & 
Rapoport, 2004b; Nariai et al., 1994; Rapoport, 2001). However, the interpretation of 
these studies is difficult due to complex interactions with endogenous lipids (Chen et 
al., 2015); metabolism and re-secretion of radiolabels in alternate forms (DeGeorge 
et al., 1989); and short time frame (seconds to hours) of these studies.  
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Understanding the major routes of uptake of circulating lipids into the brain, 
under different physiological conditions, is suggested to aid diagnosis and 
therapeutic strategies for neurological diseases (Hong, Belayev, Khoutorova, 
Obenaus, & Bazan, 2014; Jicha & Markesbery, 2010; Kim, 2014; Taha, Burnham, & 
Auvin, 2010). However, these studies do not address a critical issue: to what extent 
do circulating lipids regulate the metabolism of lipids in the brain. Many studies have 
focused on acute infusion of radiolabelled fatty acids to derive information on the 
metabolic fate of that lipid specie in the brain – be it esterification to specific 
phospholipid classes or oxidation as fuel. This approach relies on several 
methodological caveats and biological assumptions. (1) Intravenous infusion of 
radiolabelled lipids is generally limited to ‘simple’ lipids, such as NEFA or lyso-
phospholipids, which do not require incorporation into lipoproteins. In fact, the 
appearance of radiolabelled fatty acids in multiple plasma pools is often considered 
an experimental confounder as the specific contribution of a lipid class is unclear. 
However, in physiological systems, circulating lipids are continuously metabolised 
by multiple organs; incorporated into and secreted associated with lipoproteins as 
phospholipids, TG and CE; temporarily stored as TG in adipose tissue, followed by 
hydrolysis and release as circulating NEFA. (2) The metabolism of fatty acids is 
influenced by the presence, abundance and composition of other fatty acids in the 
system. Indeed, the elongation and desaturation rate of n-3 fatty acids are highly 
influenced by the abundance of n-6 fatty acids (Harnack, Andersen, & Somoza, 
2009). Furthermore, mixtures of fatty acids are known to result in altered cellular 
responses, contrasted with the individual fatty acids alone (Watt, Hoy, Muoio, & 
Coleman, 2012). Indeed, oleate regulates the channelling of palmitate down different 
metabolic pathways and can prevent palmitate induced lipotoxicity (Capel et al., 
2016; Coll et al., 2008). Given the brain is continuously exposed to circulating lipids, 
understanding the physiological regulation of cerebral lipids by circulating lipids 
requires consideration of all circulating lipids and the interaction between them, 
rather than focusing on individual lipid species.  
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5.1.2 Associated changes of the brain lipidome relative to plasma 
The plasma lipidome reflects the co-ordinated effort of a highly dynamic, 
multi-organ system responsible for synthesis, storage and delivery of lipids 
throughout the body. It is well established that the plasma lipidome is altered by the 
amount and composition of dietary fat consumed (Mattson & Grundy, 1985; Miao et 
al., 2015; Schwingshackl & Hoffmann, 2013). Immediately following a meal, dietary 
fat is digested and long-chain fatty acids esterified into TG within intestinal 
enterocytes. Intestinally derived lipoproteins, chylomicrons, are assembled and 
secreted for distribution of these dietary-derived lipids throughout the body (Mamo 
& Proctor, 1999). During this postprandial state, dietary fat composition directly 
influences the plasma lipidome. Indeed, the plasma lipidome is a product of transient 
influx of exogenous (dietary) lipids, de novo synthesis of fatty acids and constitutive 
recycling of lipids between the liver, adipose stores and tissues.  
The role of dietary lipids in modulating cerebral lipid composition is 
considered using animal model studies. However, there is a paucity of studies that 
simultaneously consider both the plasma and cerebral lipidomes. Indeed, changes in 
cerebral lipid composition are often considered a response to diet and not 
mechanistically linked to circulating lipids. Further confusion can be had due to the 
vague descriptions of ‘high-fat diets’ that abound in the literature (Warden & Fisler, 
2008). This missing mechanistic insight is exacerbated because plasma lipid 
composition is differentially altered depending on the source of lipids composing the 
diet (Buettner et al., 2006; Yaqoob et al., 1995). 
While much of the research relating diet and cerebral lipid metabolism has 
focused on dietary n-3 fatty acids, a few studies have investigated pro-inflammatory 
diets, for example diets enriched in saturated fatty acids. Borg et al. (2012) 
investigated whether high fat diets induced lipotoxicity in the hypothalamus of mice. 
Based on observations of ectopic lipid accumulation in peripheral tissue of high fat 
fed mice, Borg et al. explored whether the same mechanism occurred in the brain. 
Mice fed the high fat diet (59 % energy from fat) showed accumulation of several 
lipid classes, including dhCer, DHC, BMP, PC(O), DG, TG and several isoforms of 
ceramide. Borg et al. findings of increased abundance of lipid classes contrasts with 
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results presented in Chapter 3. Several potential reasons may explain the differences 
in observations: (1) Borg used a diet with a much higher fat content, which may have 
led to greater exposure of the brain to circulating lipids. (2) The hypothalamus is 
known to regulate appetite through sensing of circulating lipids. Excess exposure of 
the hypothalamus to circulating lipids has been shown to blunt satiety signals. (3) 
The hypothalamus does not have an intact BBB, eliminating a large component of 
lipid processing for the brain. These features may predispose this region to be 
susceptible to accumulation of lipids. However, findings by Stranahan et al. (2011) 
suggest the higher abundance of fat in the diet could account for the accumulation of 
lipids. By feeding rats a high fat (60 % energy from fat) and high fructose diet, the 
accumulation of sphingolipids was observed in the hippocampus. 
Accumulation of lipids in the brain suggests substantial dysregulation of lipid 
processing. Compared to peripheral tissue, the brain has a limited capacity to store 
lipids. In view of the lipid oversupply hypothesis, exposure to excess fatty acids 
results in accumulation of fatty acyl-CoAs and subsequently excess flux down 
glycerolipid and sphingolipid synthetic pathways. Indeed, accumulation of saturated 
long-chain acyl-CoAs have been observed in mice fed high fat diets (Posey et al., 
2009). However, the results in Chapter 3 suggest lipid oversupply was not present 
with the diet utilised in this study. Although PE(O) was elevated in the cerebral 
cortex of mice fed the SFA diet, it is unlikely to be caused by lipid oversupply. Acyl 
chain abundance is not a rate limiting factor for ether phospholipid synthesis 
("Biosynthesis of Plasmalogens in Brain," 2008). Rather, this increase in abundance 
might indicate an imbalance in processing in the endoplasmic reticulum – an early 
indicator of endoplasmic reticulum stress. Interestingly, Borg et al. observed an 
increase in PC(O) in their high fat feeding study. This may suggest a common 
mechanism through which high fat diets negatively influence the brain. Indeed, 
saturated fats have been well documented to induce endoplasmic reticulum stress in 
vitro (Watt, Hoy, et al., 2012). 
The results of Chapter 3 suggest that remodelling of phospholipids 
principally occurs as a consequence of long-term consumption of a diet modestly 
enriched in saturated fat. This finding supports previous observations in the literature 
obtained using GC-MS to measure the cerebral fatty acid composition in high fat fed 
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mice. Yu et al. (2010) observed a decrease in the abundance of polyunsaturated fatty 
acids in the brain, while the proportion of saturated fatty acids increased. In the 
present study, individual lipid species were measured without prior liberation of fatty 
acids, allowing information of lipid classes to remain. Between the hippocampus and 
cerebral cortex, 50 individual lipid species were altered. Phospholipids of the classes 
PC, PC(O), PC(P), PE, PE(O), PE(P), PI and PS were increased or decreased 
depending on composition of their acyl chains. While the overall remodelling is 
complex, several patterns emerge upon consideration of the individual species. 
Phospholipids with a high number of double bonds (6 or 7) were generally reduced, 
while those containing four double bonds were increased. The number of double 
bonds and the reciprocal relationship suggests differences in the incorporation of 
DHA versus AA. The n-3 fatty acid DHA contains 22 carbons with 6 double bonds, 
while AA is an n-6 fatty acid containing 20 carbons and 4 double bonds. 
Individually, DHA and AA are the major n-3 and n-6 fatty acids in the brain and 
together account for most of PUFAs in the brain (O'Brien & Sampson, 1965a). 
Changes in phospholipids with five double bonds show a complex relationship 
between lipid class and total length of acyl chains. For instance, phospholipids with a 
total acyl chain length of 36 carbons decreased, while those with longer chain lengths 
increased. This is except for PS 40:5 which shows a considerable decrease in both 
regions of the brain. The complex relationship between acyl chain length and 
changes in abundance of phospholipids with 5 double bonds could represent a shift in 
the utilization of DPA (22:5n-6), rather than DHA (22:6n-3) and EPA (20:5n-3) 
(Alashmali et al., 2016). The brain normally contains very little EPA and DPA (Chen 
et al., 2013), however their concentrations have been shown to change with dietary 
manipulations (Igarashi et al., 2009; Igarashi, Kim, Chang, Ma, & Rapoport, 2012; 
Lin et al., 2015). The changes in phospholipids with 5 double bonds might reflect 
losses of EPA and increases in DPA.  
Changes in the length and degree of saturation of phospholipids in the brain is 
known to cause substantial changes in the functioning of the brain (Lim et al., 2005). 
Deficiency of DHA in the brain leads to cognitive and learning deficits in animals 
(Carrie et al., 2000a; Hajjar et al., 2012; Ikemoto et al., 2001; Moriguchi, Harauma, 
& Salem, 2013) and humans (Kuratko, Barrett, Nelson, & Salem, 2013). The 
specificity for DHA has been previously demonstrated in elegant physiological 
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studies. Substitution of the essential fatty acid DHA with the similar n-6 fatty acids, 
DPA, does not rescue cognitive deficits in DHA deficient rat pups (Stark et al., 
2007). Rats were artificially reared with a base n-3 deficient diet supplemented with 
either DHA, DPA or DHA+DPA. In Morris Water Maze experiments, rats reared 
with the base n-3 deficient diet with or without DPA performed poorer than DHA 
supplemented diet. Rats fed DHA+DPA performed similarly to DHA fed animals. It 
appears that a critical membrane fluidity is required for effective neuronal and 
synaptic function (Eldho et al., 2003). Loss of DHA from these membranes results in 
less fluid membranes, which cannot be compensated for by other (n-6) fatty acids 
(Lim et al., 2005).  
The work by Lim et al. (2005) and Stark et al. (2007) suggest that DPA 
replaces DHA in the brain only when the supply of DHA is insufficient for 
requirements. When DHA is delivered to the brain in sufficient quantities, higher 
concentrations of DPA do not increase DPA or decrease DHA in the brain. The 
original hypothesis speculated that increased DPA in circulation might compete for 
DHA for incorporation into brain. This hypothesis is supported by Kim et al. (2011) 
based on graded dietary n-3 deficiency studies in rats. Lower dietary n-3 fatty acids 
lead to greater conversion of LNA/AA to DPA, which was inversely correlated with 
DHA in plasma and brain. A strength of this study was the measurement of fatty 
acids in both plasma and brain. Kim et al. suggested a ‘threshold’ concentration of n-
3 fatty acids in diets at which cerebral lipid composition changes. Alterations in brain 
DHA concentration was observed when the proportion of dietary n-3 fatty acids were 
0.8 % or below. This contrasts with plasma, where changes were observed when 
dietary n-3 fatty acid composition was reduced to 2.6 %. Extrapolating this threshold 
to the diet used in Chapter 3 and accounting for the higher fat content, these animals 
should be in the n-3 sufficient range for brain tissue. This suggests that interacting 
factors with other circulating lipids may increase the likelihood of changes in 
cerebral lipids. Kim et al. reported that the concentration of AA did not change in 
plasma or brain in any of the treatment groups investigated. This is a point of 
difference to the results of Chapter 3, where putative AA containing phospholipids 
were increased in both regions of the brain and plasma. It’s possible that higher 
consumption of saturated fats and LNA could account for these differences. Indeed, 
Cintra et al. (2012) measured the fatty acid composition of blood and hypothalamus 
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in mice fed high fat diets. The AA concentration in blood was ~40 % higher in mice 
fed the high fat diet. However, this was not accompanied by a change in 
hypothalamic AA concentration. Rather, there was a subtle rearrangement in fatty 
acid composition, reflecting lower PUFA, high MUFA and increases in some very-
long chain saturated fatty acids.  
Prior to the work presented in this thesis, no studies have reported 
associations between intact plasma and cerebral lipids. Rather, scientific work has 
focused on the fatty acid composition of plasma and the brain. Cunnane et al. (2012) 
measured the fatty acid profile of plasma and brain from MCI and AD subjects by 
first hydrolysing fatty acids from intact lipids. The only statistically significant 
association was found between the percentage of DHA liberated from circulating 
lipids and the percentage of DHA from PE species from just one region of the brain 
and only in the control group. The results from this study suggest a negligible 
relationship between circulating lipids and cerebral lipid composition. However, 
collection of tissue samples during post-mortem autopsy involves a lengthy lag-
phase which is known to significantly impact cerebral lipid composition (Lee & 
Hajra, 1991). Although not directly measuring cerebral fatty acid composition, 
Guest, Garg, Bilgin, and Grant (2013) examined the relationship between plasma 
NEFA and CSF NEFA in matching samples from human subjects. For each n-3 fatty 
acid analysed, there was no statistically significant association between circulating 
and CSF concentrations. However, an aggregate of circulating n-3 fatty acids was 
positively associated with CSF DHA concentration. Further, circulating AA was 
positively associated with CSF AA. Interestingly, Guest et al. found no significant 
associations with SFA and even observed a negative association between CSF and 
circulating oleic acid (18:1n-9). These observations are similar to those of Jumpertz 
et al. (2012). In overweight human subjects, NEFA concentrations were determined 
in plasma and CSF. In these subjects, only ALA and DHA were associated 
(positively) between plasma and CSF. 
In Chapter 3, a multivariate analysis was performed to determine the plasma 
lipid species that are jointly and independently associated with changes in the 
cerebral lipidome. The results provide a measure of ‘importance’ of each plasma 
lipid species as a function of its ability to explain changes in the cerebral lipidome. 
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Strong positive associations were observed between highly unsaturated 
phospholipids (containing 6 or 7 double bonds) in plasma and highly unsaturated 
phospholipids in both regions of the brain. Similarly, higher abundance of 
phospholipids with 4 double bonds were associated with higher abundance of 
phospholipids with 4 double bonds in the brain. The multivariate model identifies a 
reciprocal relationship between highly unsaturated species with 6 or more double 
bonds and unsaturated species containing 4 double bonds. This relationship describes 
the competition between LA and ALA for the elongation and desaturation enzymes 
responsible for producing the very-long and highly unsaturated fatty acids ARA and 
DHA, respectively (Brenna, 2002). Interestingly, there are subsets of phospholipids 
with inverse relationships between blood and brain. That is, higher concentrations in 
blood are associated with lower concentrations in the brain. The multivariate model 
revealed these lipids to be phospholipids of shorter total chain length with fewer 
double bonds. Mice consuming the SFA diet had higher circulating levels of these 
lipids, while these lipid species where higher in brains of mice consuming the control 
diet. A possible explanation for this observation involves careful consideration of the 
relative importance of lipid supply versus selectivity of fatty acids. Due to the lower 
concentration of DHA in cerebral phospholipids of SFA fed mice, membrane fluidity 
would be decreased. To correct this reduced fluidity, changes in fatty acid selectivity 
may occur (Hulbert, Turner, Storlien, & Else, 2005). This process reduces the 
incorporation of shorter and less saturated fatty acids in favour of longer and more 
unsaturated species – AA/DPA in this instance. This hypothesis suggests that lipid 
composition of neuronal membranes is altered to achieve the desired membrane 
fluidity. Indeed, it is true neuronal membranes are continuously remodelled and some 
level of selectivity of this process has been observed (Rapoport, 2008; Rapoport, 
Rao, & Igarashi, 2007).  
The strongest associations between plasma and brain lipidome were observed 
in phospholipids. However, the multivariate analysis considers all plasma lipids that 
jointly influence the brain lipidome, regardless of whether the same specie was 
altered in the brain. This is a considerable point of difference to correlation analysis 
which is typically performed (Cunnane et al., 2012; Guest et al., 2013). Therefore, it 
is also possible to identify circulating lipid species that supply fatty acids to the 
brain. We observe that several CE and TG lipid species are ranked highly as plasma 
118 
 
lipids that explained changes in the brain lipidome. Neutral lipids containing the fatty 
acids C22:6, C22:5, and C20:5 were indicated as significant regulators of cerebral 
lipids, whereas those containing C20:4 contributed much less. Furthermore, TG 
species contained a variety of fatty acids, including saturated-, monounsaturated-, 
and polyunsaturated-fatty acids. These results suggest that multiple lipid classes are 
involved in regulating lipid metabolism in the brain, including those located within 
lipoproteins.  
An interesting concept is to apply the findings of this study to predictive 
blood-based biomarkers for neurodegenerative diseases. Mapstone et al. (2014) 
described and validated a set of 10 lipids from a cohort of older aged individuals that 
predicted phenoconversion to mild cognitive impairment or Alzheimer’s disease 
within the proceeding 2-3 years. Subjects who phenoconverted had lower levels of 
all lipids on the panel. The lipid panel consisted of six PC species, one LPC, one 
PC(O), an acyl-carnitine and a hydroxylated fatty acid. Of the lipid species in the 
panel proposed by Mapstone et al., all species that were also within our lipidomics 
analysis were positively correlated with an improved cerebral lipidome, except for 
LPC 18:2. This is not surprising because four lipids identified by Mapstone et al. 
putatively contain DHA, which was shown to have beneficial effects in our study. 
However, it is not clear whether our opposite observations of LPC 18:2 is due to 
differences in metabolism of LPCs between humans and mice, or if it represents a 
specific signature of progression to neurodegeneration. Mice have very high levels of 
circulating HDL compared to humans, which is enriched in lecithin cholesterol 
acyltransferase. During the esterification of cholesterol for reverse cholesterol 
transport, LPCs are produced by the hydrolysis action on PC lipids (Santamarina-
Fojo, Lambert, Hoeg, & Brewer, 2000). It is possible the decrease in LPC 18:2 in 
Mapstone’s study represents a reduction in reverse cholesterol transport, a risk factor 
for neurodegenerative and vascular diseases (Merched, Xia, Visvikis, Serot, & Siest, 
2000; Rader, Alexander, Weibel, Billheimer, & Rothblat, 2009). 
The results presented in Chapter 3 show for the first-time, the associated 
changes in the brain lipidome relative to plasma abundance. Central to the thesis 
hypothesis, specific classes of lipids in the hippocampus and cerebral cortex were 
strongly associated with plasma lipids. Despite acknowledging the importance of 
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circulating lipids in maintaining lipid composition of the brain, no studies had 
attempted to explore the associations between the two prior to this work. Developing 
an understanding of how circulating lipids, independently and collectively, modulate 
cerebral lipid composition will lead to better diagnostic tests, therapies and strategies 
for maintaining and improving neurological health.  
 
5.1.3 Regulation of circulating and cerebral ceramides 
Aberrant lipid metabolism has been associated with AD since Alois 
Alzheimer first described the neuropathological hallmarks of AD. Throughout the 
brain, Alois described ‘extraordinarily strong accumulation of lipoid material in the 
ganglion cells, glia and vascular wall cells’. These observations have largely been 
overlooked by the field until very recently. With the tremendous advancements in the 
field of lipidomics, the biochemical alterations that Alois Alzheimer first described 
in 1906 have been elucidated. Dysregulation of sphingolipids are the most commonly 
reported lipid disorder in the brains of AD patients. A range of observations have 
been described, including increased ceramides, decreased sphingomyelins, decreased 
S1P and decreases in glycosphingolipids. Indeed, numerous reviews have been 
dedicated to describing the involvement of sphingolipids in AD. 
While there is convincing evidence for dysregulation of sphingolipids in the 
brain of AD patients, a growing number of studies are suggesting circulating 
sphingolipids may be involved in the initiation and progression of AD. Cross-
sectional and prospective studies have suggested that plasma ceramides and 
sphingomyelins are associated with cognitive decline, AD risk and disordered white-
matter microstructure (Gonzalez et al., 2016; Mielke et al., 2012; Mielke, Haughey, 
et al., 2010; Mielke et al., 2011; Mielke et al., 2016; Savica et al., 2016). 
Interestingly, several studies have suggested that circulating ceramides are predictive 
of future cognitive decline and hippocampal volume loss. These studies collectively 
suggest an involvement of circulating sphingolipids in the development and 
progression of cognitive decline and AD.  
120 
 
Despite the accumulating evidence suggesting a causal role for circulating 
ceramides in neurodegenerative disease risk, few studies have considered a lipid 
exchange axis. Several potential mechanisms have been proposed in the literature to 
explain the role of circulating sphingolipids: (1) circulating sphingolipids reflect 
changes in lipid metabolism that is occurring in the brain. This hypothesis suggests 
that measurement of plasma sphingolipids would be a surrogate marker for cerebral 
lipids – which cannot be measured in living humans. (2) Circulating sphingolipids 
are taken up by the brain where they accumulate and disrupt the cerebral lipidome. 
(3) Circulating sphingolipids indirectly influence the brain through causing 
peripheral insulin resistance or affecting the cerebrovasculature. However, to date, no 
studies have attempted to reconcile these alternate hypotheses.  
Chapter 4 explores cerebral sphingolipid homeostasis in a physiological 
context, reflecting potential capillary exchange of plasma sphingolipids with the 
brain. Using an established model of peripheral ceramide dysregulation alongside 
several sphingolipid modulating agents, putative regulatory associations were 
determined. Mice consuming the SFA diet had large increases in dihydroceramide 
and ceramide in plasma, suggesting de novo synthesis is increased. Inhibition of 
sphingolipid de novo synthesis with myriocin confirmed de novo synthesis was 
upregulated, supporting previous observations by Holland et al. (2007). However, 
Boini, Zhang, Xia, Poklis, and Li (2010) suggested acidic sphingomyelinase is 
responsible for elevated ceramides in high fat fed mice. Results in Chapter 4 do not 
agree with their observations. Inhibiting acidic sphingomyelinase with amitriptyline 
had no effect on circulating ceramides. Lastly, activation of S1P receptors had no 
effect on circulating sphingolipids. This finding supports the observations of 
Ottenlinger et al. (2016), who found FTY720 had no effect on plasma sphingolipids 
in multiple sclerosis patients. 
Contrary to the hypothesis indicated, higher circulating ceramides were not 
associated with elevated ceramides in the hippocampus or cerebral cortex. The 
results of this study are surprising in light of previous studies proposing the hepatic 
ceramide-brain axis, suggesting that peripheral ceramides are capable of increasing 
cerebral ceramides (Lyn-Cook et al., 2009a). de la Monte et al. (2010) examined this 
hypothesis by providing intraperitoneal injections of short-chain ceramides (N-
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acetyl-D-sphingosine) to Long Evans rat pups. Intraperitoneal injection of short-
chain ceramides led to increases in liver, blood and brain. However, the use of short 
chain ceramides requires the results of this study to be considered with caution. Short 
chain ceramides have a much higher water solubility than endogenous ceramides. 
Additionally, short chain ceramides are permeable of cellular membranes, allowing 
rapid movement between and within cells. Another reason the results of this study 
are surprising, are based on our understanding of the relationship between saturated 
fats and sphingolipid synthesis. The sphingolipid modulating effects of saturated 
fatty acids have been demonstrated in vitro and in vivo (Paumen, Ishida, Muramatsu, 
Yamamoto, & Honjo, 1997; Watt, Barnett, et al., 2012). Once palmitate enters a cell 
and is activated, it is a direct substrate for the rate limiting enzyme in de novo 
sphingolipid synthesis – serine-palmitoyltransferase (SPT). Serine 
palmitoyltransferase catalyses the irreversible condensation of L-serine and 
palmitoyl-CoA, forming a committed step to synthesis of sphingolipids. Indeed, it 
has been shown that infusion of palmitate is sufficient to increase de novo synthesis 
and consequently sphingolipid accumulation in blood and peripheral organs (Watt, 
Barnett, et al., 2012). Two studies have suggested saturated fatty acids can cause 
ceramide accumulation in the brain. Borg et al. (2012) fed C57BL/6 mice a high fat 
diet (59 % energy from fat) for 12 weeks. Total dihydroceramides and several 
ceramide species were elevated in the hypothalamus. Holland et al. (2011) 
intravenously infused Sprague-Dawley rats with a 20 % lard oil emulsion for 6 
hours. Hypothalamic ceramides were measured by enzymatic assay and determined 
to have increased more than 30 % compared to saline infused rats. Both studies 
analysed ceramide accumulation in the hypothalamus, an area of the brain proposed 
to be more susceptible to lipid insults (Borg et al., 2012; Martinez de Morentin et al., 
2010; McNay et al., 2010). However, the quantity of lipids the brain is exposed to in 
both studies might represent a supra-physiological amount for humans. Indeed, the 
six-hour infusion of lard oil utilised by Holland et al. represents an extraordinary 
exposure to circulating lipids. In the same study, Holland et al. utilised 
intraperitoneal injections of myriocin to prevent ceramide accrual in soleus muscle. 
However, the dose utilized was 3000-fold higher than typically used (Hojjati et al., 
2005a; Park, Rosebury, Kindt, Kowala, & Panek, 2008; Yang et al., 2009) and 
approached the LD50 for an oral dose (Kluepfel, Bagli, Baker, Charest, & Kudelski, 
1972). 
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A recent study by den Hoedt et al. (2016) investigated the effect of ApoE 
isoform and interaction with high fat/cholesterol diet (19 % butter, 0.5 % cholate and 
1.25 % cholesterol) on cerebral ceramide concentrations. In wild-type mice and mice 
expressing the human isoform of apeE4, consumption of the high fat diet did not 
alter the ceramide levels in whole brain homogenates. This finding supports the 
results observed in Chapter 4, where consumption of the SFA diet did not alter 
cerebral ceramide concentration. In addition to ceramide levels, den Hoedt et al. 
reported mRNA expression of several sphingolipid metabolising enzymes. mRNA 
expression of SPT, aSMase, nSMase2, ceramide transporters and ceramide synthases 
were reduced in the brains of wild-type mice fed the high fat diet. Reduced 
expression of these sphingolipid metabolizing enzymes suggest a co-ordinated effort 
to prevent ceramide accumulation. Indeed, results of Chapter 4 suggest a small but 
non-significant decrease in nearly all ceramide species in both regions of the brain 
with consumption of the SFA diet. A change in the regulation of sphingolipid 
metabolism towards a phenotype observed by den Hoedt et al. could explain this 
minor decrease. 
Results presented in Chapter 4 suggest a negative association between 
circulating ceramides and HPF ceramides. Presently, the physiological function of 
circulating ceramides is unclear, however lines of evidence suggest they may exert 
biological effects without overtly raising tissue concentrations. Boon et al. (2013) 
isolated the biological effects of lipoprotein-associated ceramide by infusing mice 
with LDL artificially enriched in ceramides. Three hours of infusion with LDL-
enriched with ceramides induced insulin resistance and inflammation, compared to 
LDL. Despite a dramatic reduction in skeletal muscle insulin sensitivity, skeletal 
muscle ceramides remained unchanged. Compared to whole muscle, ceramides 
tended to increase in isolated plasma membranes. Multiple mechanisms connect 
elevated plasma membrane ceramides to insulin resistance (Chavez & Summers, 
2012; Summers, 2006). Boon et al. suggested that circulating ceramides may mediate 
their actions by lipid-soluble exchange with the outer-leaflet of the plasma 
membrane. However, model membranes and molecular dynamic simulations suggest 
slow rates of transfer for ceramides (Simon, Holloway, & Gear, 1999). Certainly, the 
rate of transfer by any method is tissue, lipid and lipoprotein dependent 
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(Boyanovsky, Karakashian, King, Giltiay, & Nikolova-Karakashian, 2003a; Morita 
et al., 2004; Xu & Tabas, 1991; Zolnik et al., 2008). 
If circulating ceramides enter the brain, their metabolic fate is not known. 
Circulating lipoproteins can be taken up into endothelial cells through internalisation 
of lipoprotein-lipoprotein receptor complexes. Once inside the cell, complexes can 
be targeted for lysosomal degradation where lipid contents are hydrolysed. 
Lysosomes are enriched with sphingolipid degrading enzymes, including 
ceramidases which hydrolyse ceramides to sphingosine. Once sphingolipids are 
broken down to sphingosine, they may be re-acylated to ceramides or phosphorylated 
to S1P (Kitatani, Idkowiak-Baldys, & Hannun, 2008). A recent finding by Gulbins et 
al. (2016) suggests cerebral endothelial cells can release ceramides into the 
extracellular space of the hippocampus. Using confocal microscopy, Gulbins et al. 
observed that endothelial cells of the hippocampus became enriched with ceramides 
when treating mice with glucocorticosterone. Extracellular extracts of the 
hippocampus of stressed mice were enriched in ceramides. As ceramides are 
insoluble in aqueous environments, it was speculated that ceramides were secreted as 
micro vessels. Interestingly, these effects were abrogated by cotreatment with 
amitriptyline – suggesting an involvement of lysosomal sphingolipid metabolism. 
However, as acknowledged by Gulbins et al., glucocorticosterone is not known to 
activate acidic sphingomyelinase. Rather, glucocorticosterone causes large elevations 
in circulating ceramides, principally through de novo synthesis in the liver (Holland 
et al., 2007). It is possible the increase in ceramides observed were not generated in 
situ, but a result of increased uptake of circulating ceramide by hippocampal 
endothelial cells. 
Chapter 4 explored cerebral sphingolipid homeostasis in a physiological 
context, reflecting potential capillary exchange of plasma and CSF lipids, 
degradation and efflux. Concomitant measures of plasma and cerebral lipids enabled 
exploration of putative regulatory associations. Opposite to the thesis hypothesis, 
cerebral ceramides were not positively associated with circulating ceramides. 
Alterations in the plasma lipidome are commonly indicated in neurodegenerative 
disorders and increasingly implicated in a causal context. However, there remains a 
paucity of studies which have interrogated the capillary axis central to lipid kinetics. 
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Understanding the mechanisms involved will lead to improved understanding of 
disease pathogenesis and diagnostic tests. 
 
5.2 Limitations of the present studies 
The genetically un-manipulated mice used in this study are commonly used 
rodent models for the study of lipid metabolism of blood and the brain. In these mice, 
the distribution of lipids between structures of the brain closely resemble that of 
humans (Bozek et al., 2015; Chan et al., 2012b; Park et al., 2017). However, several 
differences exist between mice and humans in the abundance and distribution of 
lipids in circulation (Gordon et al., 2015; Ishikawa et al., 2015; Yin et al., 2012). 
When considering the distribution of circulating lipoproteins, LDL is the most 
abundant lipoprotein class in blood, whereas in mice, HDL is the most abundant. 
This difference in abundance of lipoprotein classes is reflected in the difference in 
abundance of lipid classes – as lipid classes are not uniformly distributed among 
lipoprotein classes. These differences can be observed in the lipidomic datasets, such 
as the low abundance of TG and high abundance of LPC in mouse plasma (Ishikawa 
et al., 2015; Yin et al., 2012). Given this was the first-time associations between 
whole plasma and brain lipidomes were assessed, the significance of this difference 
is not known. Certainly, circulating TG is a major source of lipids for many 
peripheral organs and lipoprotein lipases are present on the BBB. 
In both studies presented in this thesis, the abundance of lipids in plasma and 
brain were concomitantly determined and putative associations explored. Therefore, 
associations were assessed in the ‘steady-state’ and might not reflect dynamic 
associations between the two (Castro-Perez et al., 2011). Chapter 3 highlights the 
remarkable stability of the brain lipidome despite substantial changes in circulating 
lipids. The circulating ceramide hypothesis suggests that elevated levels of 
circulating ceramides accumulate in the brain. However, in physiologically relevant 
models, changes in plasma ceramides appear unlikely to induce changes in cerebral 
ceramides, perhaps because of compensatory mechanisms that ameliorate increased 
blood-to-brain kinetics (den Hoedt et al., 2016). These mechanisms may include 
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altered kinetics across the BBB, changes in abundance of regulatory enzymes, 
increased degradation or secretion of lipids. Since kinetic measurements were not 
explored in this candidacy, it is not possible to elucidate the mechanisms through 
which cerebral ceramide homeostasis is achieved.   
The experiments in Chapters 3 and 4 utilised a targeted lipidomics platform 
using mass spectrometry (Weir et al., 2013b). Liquid chromatography electrospray 
ionisation tandem mass spectrometry allowed targeted analysis of lipids. 
Chromatographic separation and scheduled precursor/product transitions were 
optimized to simultaneously measure many lipid classes. While acyl chain 
composition information can be determined, a shortcoming of this approach is that 
double bond position cannot be determined. Differences in double bond position (n-
3, n-6 and n-9) do not alter the precursor/product transitions in conventional LC-ESI-
MS/MS platforms. Therefore, it is possible that some lipids may appear over-
represented due to multiple contributions from different lipids. For instance, the lipid 
specie PE-40:5 may be a combination of PE-20:0/20:5n3 and PE-18:0/22:5n6, PE-
20:1/20:4n6 or several other variants. With adequate chromatography, these species 
can be separated and elucidation of each specie determined in negative ESI mode. 
However, in the current configuration, isomeric n-3 and n-6 species were not 
chromatographically separated. Therefore, given the current instrumentation used, it 
is not possible to confidently designate a lipid as containing n-3, n-6 or n-9 fatty 
acids. 
 
5.3 Future directions for research 
The principal findings presented in this thesis suggest a highly-regulated axis 
through which circulating lipids regulate lipids in the brain. In a physiological system 
associated changes of the brain lipidome relative to plasma abundance may reflect 
changes in kinetics across the BBB, cerebral metabolic responses and/or changes in 
degradation and efflux through CSF transport. Potential mechanisms include via a 
consequence of altered blood-to-brain kinetics; via altered cerebral metabolism of 
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lipids; alteration of capillary architecture and function; or indirectly, for example via 
changes in redox homeostasis. 
The results of Chapter 4 suggest an incomplete model for how circulating 
ceramides may influence neurodegenerative disease risk. Abundant evidence from 
cross sectional and longitudinal studies highly supports a causative role of ceramides. 
However, this mechanism of action is still not elucidated. For the first time, it was 
demonstrated that circulating ceramides did not contribute to ceramide accrual in the 
brain, nor reflect cerebral ceramide metabolism. Rather, specific negative 
associations were shown between plasma and HPF. Several lines of evidence suggest 
circulating ceramides may increase neurodegenerative disease risk through 
compromising the BBB: (1) The BBB is the interface between blood and brain, and 
therefore continuously exposed to circulating ceramides. It is possible that long-term 
exposure compromises the integrity of the BBB, opening the brain up to potentially 
neurotoxic plasma components (Symons & Abel, 2013; van Doorn, Nijland, Dekker, 
Witte, Lopes-Pinheiro , et al., 2012). (2) Ceramides are known to induce endothelial 
dysfunction in vivo (Bharath et al., 2015). Multiple pathways that induce ceramide 
accumulation in endothelial cells (obesity, high fat diets, corticosteroids) have been 
shown to prevent insulin signalling and nitric oxide generation of endothelial cells 
(Mehra et al., 2014; Smith, Visioli, Frei, & Hagen, 2006; Zhang et al., 2012a). These 
metabolic effects are also accompanied by oxidative stress, a well characterised 
effect of ceramide accumulation (Corda, Laplace, Vicaut, & Duranteau, 2001; Li et 
al., 2002). (3) Increased S1P is thought to restore BBB damage through action of S1P 
receptors and possibly through restoration of aberrant ceramide levels (Prager, 
Spampinato, & Ransohoff, 2015; Spampinato et al., 2015; van Doorn, Nijland, 
Dekker, Witte, Lopes-Pinheiro , et al., 2012). Clearly, delineating the mechanism 
through which circulating ceramides influence the brain is a key area for future 
studies to be considered. 
Most of the studies examining physiological regulation of cerebral lipids have 
been completed in otherwise healthy animals. It is not unreasonable to expect the 
metabolic flux and metabolism of lipids to change considerably with cellular stress 
and inflammation. Indeed, cerebrovascular inflammation, associated with BBB 
disruption, has been shown to alter the rates of passage of molecules between blood 
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and the brain (Takechi, Pallebage-Gamarallage, et al., 2013a). In a healthy organism, 
the rate of vesicular mediated transcytosis across the BBB is low. However, during 
times of vascular stress, there is a considerable increase in the rate of non-specific 
vesicular transcytosis. Electron micrographs show increased caveolae mediated 
endocytosis of cerebral capillaries during stress (Lossinsky, Vorbrodt, & 
Wisniewski, 1983; Povlishock, Kontos, Wei, Rosenblum, & Becker, 1980). Caveolae 
have been suggested to carry circulating lipoproteins across endothelial cell layers 
(Schubert et al., 2001). Indeed, the perivascular abundance of apolipoprotein B, an 
exclusive marker of peripherally derived lipoproteins, increases considerably 
following inflammatory insults in mice (Takechi, Galloway, Pallebage-Gamarallage, 
Wellington, et al., 2010). Interestingly, ceramides have been identified as a bioactive 
lipid associated with caveolae (Czarny, Liu, Oh, & Schnitzer, 2003; Der, Cui, & Das, 
2006; Hajduch et al., 2008; Kuebler, Yang, Samapati, & Uhlig, 2010). The increased 
delivery of lipids to the brain during times of stress do not appear to be exclusive to 
lipoproteins. A study by Karmi et al. (2010) used positron emission tomography to 
measure the rate of fatty acid uptake into the brain of patients with metabolic 
syndrome compared to healthy controls. Patients with metabolic syndrome showed 
50-86 % greater uptake of fatty acids into their brain. The results of these studies 
suggest that during times of stress, alterations in lipid uptake kinetics occur, which 
may occur through an alteration of capillary architecture and function. Indeed, the 
endothelium of the BBB forms the sole exchange barrier between the brain and 
blood. As such, it is exposed to circulating lipids and lipoproteins to a high degree. 
Therefore, it is susceptible to many of the physiological and pathological effects of 
lipids and may represent a key component in regulation of the cerebral lipidome by 
circulating lipids.  
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Appendix II: R Code for isotope distribution, partial 
least squares, double cross validation and permutation tests 
R code to calculate exact mass and isotope envelope. 
## Generate molecular formula for lipids 
FA<-    c("12_0", "13_0", "14_0", "15_0", 
"16_0","16_1","17_0","17_1","18_0","18_1","18_2","18_3","20_0","20_1
","20_2","20_3","20_4","20_5","22_0","22_1","22_5","22_6","24_0","24
_1","26_0","26_1") 
length<-c( 12,     13,     14,     15,     16,    16,    17,    17,    
18,    18,    18,    18,    20,    20,    20,    20,    20,    20,    
22,    22,    22,    22,    24,    24,    26,    26) 
db<-    c( 0,      0,      0,      0,      0,     1,     0,     1,     
0,     1,     2,     3,     0,     1,     2,     3,     4,     5,     
0,     1,     5,     6,     0,     1,     0,     1) 
fattyAcids<-data.frame(FA=FA,length=length,db=db) 
 
headGroup<-
c("PC","PE","PS","PI","OH","TG","Pi","Glu","Lac","Sulfatide") 
 
 
##  Coefficients 
#   Gly Chol Sph PC  PE  PS  PI  OH  Pi Glu Lac Sul SN1  DB SN2  DB 
SN3  DB (P) (O) sn1 sn2 sn3 offset 
C<-c( 3, 27,  0,  5,  2,  3,  6,  0,  0,  6, 12,  6,  1,  0,  1,  0,  
1,  0,  0,  0,  0,  0,  0,  0) 
H<-c( 3, 41,  0, 12,  6,  6, 11,  0,  1, 10, 20, 10,  2, -2,  2, -2,  
2, -2,  0,  2, -2, -2, -2,  5) 
N<-c(-1, -1,  0,  1,  1,  1,  0,  0,  0,  0,  0,  0,  0,  0,  0,  0,  
0,  0,  0,  0,  0,  0,  0,  1) 
O<-c( 2,  0,  0,  3,  3,  5,  8,  0,  3,  5, 10,  8,  0,  0,  0,  0,  
0,  0, -1, -1,  1,  1,  1,  1) 
P<-c( 0,  0,  0,  1,  1,  1,  1,  0,  1,  0,  0,  0,  0,  0,  0,  0,  
0,  0,  0,  0,  0,  0,  0,  0) 
S<-c( 0,  0,  0,  0,  0,  0,  0,  0,  0,  0,  0,  1,  0,  0,  0,  0,  
0,  0,  0,  0,  0,  0,  0,  0) 
elementalCoef<-matrix(c(C,H,N,O,P,S),ncol=6,dimnames = 
list(c("Glycerol","Cholesterol","Sphingoid","PC","PE","PS","PI","OH"
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,"Pi","Glu","Lac","Sulfatide","SN1-chain","SN1-DB","SN2-chain","SN2-
DB","SN3-Chain","SN3-
DB","(P)","(O)","sn1","sn2","sn3","offset"),NULL)) 
 
 
## Generate lipid structure 
generateLipid<-
function(backBone="Glycerol",headGroup="PC",acylSN1="18_0",acylSN2="
18_1",acylSN3=NA,modification=NA) { 
  composition<-numeric(24) 
  if(backBone=="Glycerol") { 
    composition[1:3]<-c(1,0,0) 
  } else if(backBone=="Cholesterol") { 
    composition[1:3]<-c(0,1,0) 
    if(!is.na(acylSN1)) { 
      headGroup=NA 
    } 
    acylSN2<-NA 
    acylSN3<-NA 
  } else if(backBone=="Sphingoid") { 
    composition[1:3]<-c(0,0,1) 
    acylSN3<-NA 
  } 
  if(!is.na(headGroup)) { 
    if(headGroup=="PC") { 
      composition[4:12]<-c(1,0,0,0,0,0,0,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="PE") { 
      composition[4:12]<-c(0,1,0,0,0,0,0,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="PS") { 
      composition[4:12]<-c(0,0,1,0,0,0,0,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="PI") { 
      composition[4:12]<-c(0,0,0,1,0,0,0,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="OH") { 
      composition[4:12]<-c(0,0,0,0,1,0,0,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="Pi") { 
      composition[4:12]<-c(0,0,0,0,0,1,0,0,0) 
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    } else if(headGroup=="Glu") { 
      composition[4:12]<-c(0,0,0,0,0,0,1,0,0) 
      acylSN3<-NA 
    } else if(headGroup=="Lac") { 
      composition[4:12]<-c(0,0,0,0,0,0,0,1,0) 
      acylSN3<-NA 
    } else if(headGroup=="Sulfatide") { 
      composition[4:12]<-c(0,0,0,0,0,0,0,0,1) 
      acylSN3<-NA 
    }  
  } else { 
    composition[4:12]<-c(0,0,0,0,0,0,0,0,0) 
  } 
  
if(backBone=="Glycerol"||(backBone=="Cholesterol"&!is.na(acylSN1))) 
{ 
    composition[13]<-
fattyAcids$length[which(fattyAcids$FA==acylSN1)] 
    composition[14]<-fattyAcids$db[which(fattyAcids$FA==acylSN1)] 
    if(!is.na(acylSN2)) { 
      composition[15]<-
fattyAcids$length[which(fattyAcids$FA==acylSN2)] 
      composition[16]<-fattyAcids$db[which(fattyAcids$FA==acylSN2)] 
    } 
    if(!is.na(acylSN3)) { 
      composition[17]<-
fattyAcids$length[which(fattyAcids$FA==acylSN3)] 
      composition[18]<-fattyAcids$db[which(fattyAcids$FA==acylSN3)] 
    } 
  } else if(backBone=="Sphingoid") { 
    composition[13]<-
fattyAcids$length[which(fattyAcids$FA==acylSN1)] 
    composition[14]<-fattyAcids$db[which(fattyAcids$FA==acylSN1)] 
    if(!is.na(acylSN2)) { 
      composition[15]<-
fattyAcids$length[which(fattyAcids$FA==acylSN2)] 
      composition[16]<-fattyAcids$db[which(fattyAcids$FA==acylSN2)] 
    } 
  } 
  if(!is.na(modification)) { 
    if(modification=="P") { 
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      composition[19:20]<-c(1,0) 
    } else if(modification=="O") { 
      composition[19:20]<-c(0,1) 
    } 
  } 
  if(!is.na(acylSN1)) { 
    composition[21]<-1 
  } 
  if(!is.na(acylSN2)) { 
    composition[22]<-1 
  } 
  if(!is.na(acylSN3)) { 
    composition[23]<-1 
  } 
  composition[24]<-1 
  return(composition) 
} 
 
 
## Calculate isotope envolope and exact mass 
elements<-  c("C",       "H",      "N",       "O",       "P",       
"S") 
mass1<-     c(12,        1.007825, 14.003074, 15.994915, 30.973762, 
31.972071) 
mass2<-     c(13.003355, 2.014102, 15.000109, 17.99916,  30.973762, 
33.967867) 
abundance<- c(0.9893,    0.999885, 0.996360,  0.99757,   1.0,       
0.9499) 
 
natural.isotopic.abundance<-
data.frame(elements=elements,mass1=mass1,mass2=mass2,abundance=abund
ance) 
 
isotope.distribution<-function(compound) { 
  output.combined<-matrix(c(0,1),nrow=1,ncol=2) 
  for(p in 1:length(elements)) { 
    n<-compound[p] 
    mass1<-natural.isotopic.abundance[p,2] 
    mass2<-natural.isotopic.abundance[p,3] 
    abundance<-natural.isotopic.abundance[p,4] 
    mass.dist<-matrix(0,nrow=n+1,ncol=2) 
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    for(k in 0:n) { 
      mass.dist[k+1,1]<-mass1*k+(n-k)*mass2 
      mass.dist[k+1,2]<-dbinom(k,n,abundance) 
    } 
    eval(parse(text=paste("output.combined<-
rbind(",paste(rep("output.combined",nrow(mass.dist)),collapse=","),"
)",sep=""))) 
    output.combined[,1]<-
output.combined[,1]+rep(mass.dist[,1],each=nrow(output.combined)/nro
w(mass.dist)) 
    output.combined[,2]<-
output.combined[,2]*rep(mass.dist[,2],each=nrow(output.combined)/nro
w(mass.dist)) 
  } 
  output.combined<-
output.combined[which(output.combined[,2]>0.0001),,drop=FALSE] 
  output.combined[,2]<-output.combined[,2] 
  output.combined<-output.combined[order(output.combined[,1]),] 
  return(output.combined) 
} 
 
 
## Simulate the low resolution of a quadrupole mass filter 
quadrupole<-function(compound) { 
  isotope.envolope<-isotope.distribution(compound) 
  mz<-seq(min(isotope.envolope[,1])-
1,max(isotope.envolope[,1])+1,0.01) 
   
  count<-numeric(length(mz)) 
  out<-numeric(length(mz)) 
   
  for(i in 1:nrow(isotope.envolope)) { 
    position<-which.min(abs(mz-isotope.envolope[i,1])) 
    count[position]<-count[position]+isotope.envolope[i,2] 
  } 
   
  conv<-dnorm(seq(-5,5,0.1),0,1.5) 
  convolution<-convolve(count,conv/max(conv),type="o")[51:752] 
  names(convolution)<-mz 
  return(convolution) 
} 
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# Generate PC(18:0/22:6) 
PC_18_0_22_6<-
generateLipid("Glycerol",headGroup="PC",acylSN1="18_0",acylSN2 = 
"22_6")%*%elementalCoef 
envolope<-quadrupole(PC_18_0_22_6) 
 
# Plot isotope envolope 
plot(names(envolope),envolope,type='l',xlab='m/z',ylab='isotope 
abundance',main='PC(18:0/22:6') 
lines(isoltope.distribution(PC_18_0_22_6),type='h',col='red') 
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R code to perform partial least squares, double cross-validation and 
permutation tests. 
library(mixOmics) 
## Mean centre and unit-variance scale datasets 
Plasma<-scale(Plasma) 
CTX<-scale(CTX) 
HPF<-scale(HPF) 
 
#============================================================= 
# 
#   Double cross validation for CTX/Plasma 
# 
#============================================================= 
n<-nrow(Plasma) 
CV.pls.MSEP<-matrix(NA,nrow=n,ncol=ncol(CTX)) 
list.lv<-rep(0,nrow(Plasma)) 
for(i in 1:n) { 
  CTX.train<-CTX[-i,] 
  CTX.test<-CTX[i,,drop=FALSE] 
  Plasma.train<-Plasma[-i,] 
  Plasma.test<-Plasma[i,,drop=FALSE] 
   
  train.pls<-pls(Plasma.train,CTX.train,ncomp=5,mode="regression") 
  train.perf<-perf(train.pls,validation="loo") 
  MSEP<-colMeans(train.perf$MSEP) 
  optim.lv<-which(MSEP==min(MSEP)) 
   
  CTX.pls<-
pls(Plasma.train,CTX.train,ncomp=optim.lv,mode="regression") 
  CTX.test.hat<-predict(CTX.pls,Plasma.test) 
  CV.pls.MSEP[i,]<-(CTX.test.hat$predict[,,optim.lv]-CTX.test)^2 
  list.lv[i]<-optim.lv 
} 
 
CTX.sig<-sum(colMeans(CV.pls.MSEP)) 
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#============================================================= 
# 
#   Permutation test for CTX/Plasma 
# 
#============================================================= 
B<-1000 
out<-rep(0,B) 
for(p in 1:B) { 
  CV.pls.MSEP<-matrix(NA,nrow=n,ncol=ncol(CTX)) 
  list.lv<-rep(0,nrow(Plasma)) 
  perm<-sample(1:19,replace=FALSE) 
  CTX.perm<-CTX[perm,] 
  Plasma.perm<-Plasma 
  for(i in 1:n) { 
    CTX.train<-CTX.perm[-i,] 
    CTX.test<-CTX.perm[i,,drop=FALSE] 
    Plasma.train<-Plasma.perm[-i,] 
    Plasma.test<-Plasma.perm[i,,drop=FALSE] 
     
    train.pls<-pls(Plasma.train,CTX.train,ncomp=3,mode="regression") 
    train.perf<-perf(train.pls,validation="loo") 
    MSEP<-colMeans(train.perf$MSEP) 
    optim.lv<-which(MSEP==min(MSEP)) 
     
    CTX.pls<-
pls(Plasma.train,CTX.train,ncomp=optim.lv,mode="regression") 
    CTX.test.hat<-predict(CTX.pls,Plasma.test) 
    CV.pls.MSEP[i,]<-(CTX.test.hat$predict[,,optim.lv]-CTX.test)^2 
    list.lv[i]<-optim.lv 
  } 
  out[p]<-sum(colMeans(CV.pls.MSEP)) 
} 
 
hist(out,breaks=50) 
abline(v=CTX.sig) 
 
write.table(out,file="lipidomics.pls.CTX.permutation.test.csv",sep="
,") 
quantile(out,probs=c(0.025,0.975)) 
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#============================================================= 
# 
#   Double cross validation for HPF/Plasma 
# 
#============================================================= 
n<-nrow(Plasma) 
CV.pls.MSEP<-matrix(NA,nrow=n,ncol=ncol(HPF)) 
list.lv<-rep(0,nrow(Plasma)) 
for(i in 1:n) { 
  HPF.train<-HPF[-i,] 
  HPF.test<-HPF[i,,drop=FALSE] 
  Plasma.train<-Plasma[-i,] 
  Plasma.test<-Plasma[i,,drop=FALSE] 
   
  train.pls<-pls(Plasma.train,HPF.train,ncomp=5,mode="regression") 
  train.perf<-perf(train.pls,validation="loo") 
  MSEP<-colMeans(train.perf$MSEP) 
  optim.lv<-which(MSEP==min(MSEP)) 
   
  HPF.pls<-
pls(Plasma.train,HPF.train,ncomp=optim.lv,mode="regression") 
  HPF.test.hat<-predict(HPF.pls,Plasma.test) 
  CV.pls.MSEP[i,]<-(HPF.test.hat$predict[,,optim.lv]-HPF.test)^2 
  list.lv[i]<-optim.lv 
} 
 
HPF.sig<-sum(colMeans(CV.pls.MSEP)) 
 
#============================================================= 
# 
#   Permutation test for HPF/Plasma 
# 
#============================================================= 
B<-1000 
out<-rep(0,B) 
for(p in 1:B) { 
  CV.pls.MSEP<-matrix(NA,nrow=n,ncol=ncol(HPF)) 
  list.lv<-rep(0,nrow(Plasma)) 
  perm<-sample(1:19,replace=FALSE) 
  HPF.perm<-HPF[perm,] 
  Plasma.perm<-Plasma 
221 
 
  for(i in 1:n) { 
    HPF.train<-HPF.perm[-i,] 
    HPF.test<-HPF.perm[i,,drop=FALSE] 
    Plasma.train<-Plasma.perm[-i,] 
    Plasma.test<-Plasma.perm[i,,drop=FALSE] 
     
    train.pls<-pls(Plasma.train,HPF.train,ncomp=3,mode="regression") 
    train.perf<-perf(train.pls,validation="loo") 
    MSEP<-colMeans(train.perf$MSEP) 
    optim.lv<-which(MSEP==min(MSEP)) 
     
    HPF.pls<-
pls(Plasma.train,HPF.train,ncomp=optim.lv,mode="regression") 
    HPF.test.hat<-predict(HPF.pls,Plasma.test) 
    CV.pls.MSEP[i,]<-(HPF.test.hat$predict[,,optim.lv]-HPF.test)^2 
    list.lv[i]<-optim.lv 
  } 
  out[p]<-sum(colMeans(CV.pls.MSEP)) 
} 
 
hist(out,breaks=50) 
abline(v=HPF.sig) 
 
write.table(out,file="lipidomics.pls.HPF.permutation.test.csv",sep="
,") 
quantile(out,probs=c(0.025,0.975)) 
 
